<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="7c48960d-6e45-46c0-a490-78bf8f92d8e7"/>
   <code code="34391-3" displayName="HUMAN PRESCRIPTION DRUG LABEL" codeSystem="2.16.840.1.113883.6.1"/>
   <title>
      <content styleCode="bold">These highlights do not include all the information needed to use </content>
      <content styleCode="bold">PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE CAPSULES</content>
      <content styleCode="bold"> safely and effectively. See full prescribing information for </content>
      <content styleCode="bold">PHENTERMINE AND TOPIRAMATE EXTENDED-RELEASE CAPSULES</content>
      <content styleCode="bold">.<br/>
         <br/>
      </content>
      <content styleCode="bold">PHENTERMINE</content>
      <content styleCode="bold"> and </content>
      <content styleCode="bold">TOPIRAMATEÂ </content>
      <content styleCode="bold">extended-release capsules, for oral use, CIV<br/>
      </content>
      <content styleCode="bold">Initial U.S. Approval: 2012</content>
   </title>
   <effectiveTime value="20241212"/>
   <setId root="918df93d-e033-4419-adcc-e21655ef8158"/>
   <versionNumber value="3"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id extension="022629579" root="1.3.6.1.4.1.519.1"/>
            <name>Teva Pharmaceuticals, Inc.</name>
            <assignedEntity>
               <assignedOrganization/>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="4c4b49a8-65f4-46d1-81d4-36d5575ad380"/>
               <code code="48780-1" displayName="SPL listing data elements section" codeSystem="2.16.840.1.113883.6.1"/>
               <effectiveTime value="20240228"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3297" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phentermine and topiramate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine and topiramate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="3.75"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="23"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOPIRAMATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TOPIRAMATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3297-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250507"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204982" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250507"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" displayName="CIV" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48331" displayName="orange" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">WPI;2196</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="18" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3296" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phentermine and topiramate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine and topiramate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="7.5"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="46"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOPIRAMATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TOPIRAMATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="L06K8R7DQK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FD&amp;C BLUE NO. 2</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3296-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250507"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204982" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250507"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" displayName="CIV" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48329" displayName="green" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">WPI;2195</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="19" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-2299" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phentermine and topiramate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine and topiramate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="11.25"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="69"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOPIRAMATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TOPIRAMATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="EX438O2MRT" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE YELLOW</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-2299-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250507"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204982" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250507"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" displayName="CIV" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48330" displayName="yellow" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>light yellow</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">WPI;2299</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="22" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="0480-3295" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>Phentermine and topiramate</name>
                        <formCode code="C42916" displayName="CAPSULE, EXTENDED RELEASE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>Phentermine and topiramate</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIM">
                           <quantity>
                              <numerator unit="mg" value="15"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0K2I505OTV" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PHENTERMINE HYDROCHLORIDE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="C045TQL4WP" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>PHENTERMINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator unit="mg" value="92"/>
                              <denominator unit="1" value="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TOPIRAMATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="0H73WJJ391" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>TOPIRAMATE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="ETJ7Z6XBU4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SILICON DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="D9C330MD8B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>COPOVIDONE K25-31</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7Z8S9VYZ4B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ETHYLCELLULOSES</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="2G86QN327L" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>GELATIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="R75537T0T4" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (5 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6OZP39ZG8H" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYSORBATE 80</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="C151H8M554" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SUCROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="O8232NY3SJ" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>STARCH, CORN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="7SEV7J4R1U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TALC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1K09F3G675" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERRIC OXIDE RED</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="5138Q19F1X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>AMMONIA</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XM0M87F357" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>FERROSOFERRIC OXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="6DC9Q167V3" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>PROPYLENE GLYCOL</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="46N107B71O" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SHELLAC</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator unit="1" value="30"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="0480-3295-56" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43169" displayName="BOTTLE" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" displayName="Type 0: Not a Combination Product" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250507"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA204982" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" displayName="ANDA" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250507"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <policy classCode="DEADrugSchedule">
                           <code code="C48677" displayName="CIV" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </policy>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48325" displayName="white" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48326" displayName="red" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV">
                              <originalText>dark scarlet</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">WPI;2194</value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value value="1" xsi:type="INT"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value code="C48336" displayName="CAPSULE" codeSystem="2.16.840.1.113883.3.26.1.1" xsi:type="CV"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value unit="mm" value="23" xsi:type="PQ"/>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" displayName="ORAL" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">
               <id root="a8f1111c-3d64-41d7-9d82-aca0ae1b15dc"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <text>
                  <paragraph>Phentermine and topiramate extended-release capsules are indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Adults with obesity</item>
                     <item>Adults with overweight in the presence of at least one weight-related comorbid condition</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Limitations of Use</content>
                  </paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established.</item>
                     <item>The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription drugs, over-the-counter drugs, and herbal preparations, have not been established.</item>
                  </list>
                  <paragraph>
                     <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules are a combination of phentermine, a sympathomimetic amine anorectic, and topiramate, indicated in combination with a reduced-calorie diet and increased physical activity to reduce excess body weight and maintain weight reduction long term in:</paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>Adults with obesity (<linkHtml href="#LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>)</item>
                           <item>Adults with overweight in the presence of at least one weight-related comorbid condition (<linkHtml href="#LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                        </paragraph>
                        <list listType="unordered" styleCode="Disk">
                           <item>The effect of phentermine and topiramate extended-release capsules on cardiovascular morbidity and mortality has not been established (<linkHtml href="#LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>).</item>
                           <item>The safety and effectiveness of phentermine and topiramate extended-release capsules in combination with other products intended for weight loss, including prescription and over-the-counter drugs, and herbal preparations, have not been established (<linkHtml href="#LINK_e54eaf0c-aa13-4d44-911f-9bfe9f1fdc5c">1</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_94109e27-eafa-4c0d-8722-491533474dd5">
               <id root="aa1f8c2b-f3ee-4aa6-a91c-f78efe0391cc"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <text/>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Take orally once daily in morning. Avoid administration in evening to prevent insomnia (<linkHtml href="#LINK_4e521d79-6299-4a58-9e85-f9597825b434">2.2</linkHtml>).</item>
                           <item>Recommended starting dosage is 3.75 mg/23 mg (phentermine mg/topiramate mg) daily for 14 days; then increase to 7.5 mg/46 mg daily (<linkHtml href="#LINK_4e521d79-6299-4a58-9e85-f9597825b434">2.2</linkHtml>).</item>
                           <item>Escalate dosage based on weight loss in adults. See the Full Prescribing Information for details regarding discontinuation or dosage escalation (<linkHtml href="#LINK_4e521d79-6299-4a58-9e85-f9597825b434">2.2</linkHtml>).</item>
                           <item>Gradually discontinue 15 mg/92 mg dosage to prevent possible seizure (<linkHtml href="#LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">2.3</linkHtml>).</item>
                           <item>Do not exceed 7.5 mg/46 mg dosage for patients with moderate or severe renal impairment or patients with moderate hepatic impairment (<linkHtml href="#LINK_364260b5-aa45-4a0a-a2a2-699a569736cd">2.4</linkHtml>, <linkHtml href="#LINK_e02e7bff-ca62-45b3-b30f-b285776673af">2.5</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_879ff41f-74a8-4052-9494-fb0c0211107f">
                     <id root="3dd136d4-4929-4b5a-8a42-0d31ed476a9b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.1 Recommended Testing Prior to and During
Treatment with Phentermine and Topiramate Extended-Release Capsules</title>
                     <text>
                        <paragraph>Prior to phentermine and topiramate extended-release capsule initiation and during treatment with phentermine and topiramate extended-release capsules, the following is recommended:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Obtain a negative pregnancy test before initiating phentermine and topiramate extended-release capsules in patients who can become pregnant and monthly during phentermine and topiramate extended-release capsule therapy. Phentermine and topiramate extended-release capsules are contraindicated during pregnancy <content styleCode="italics">[see Contraindications (<linkHtml href="#www.splportal.comLINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>), Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>), and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_c8d68c91-d39c-4861-a99b-63f774483a8d">8.3</linkHtml>)]</content>.</item>
                           <item>Obtain a blood chemistry profile that includes bicarbonate, creatinine, and potassium in all patients, and glucose in patients with type 2 diabetes mellitus on antidiabetic medication prior to initiating phentermine and topiramate extended-release capsule treatment and periodically during treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>, <linkHtml href="#LINK_b180e995-2372-4766-8c58-f170b8da4e8b">5.8</linkHtml>, <linkHtml href="#LINK_7850101b-a9e8-41ed-b234-615c1f24fc79">5.12</linkHtml>)]</content>.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4e521d79-6299-4a58-9e85-f9597825b434">
                     <id root="a0d10f63-a72c-4de6-91ef-3e53dea617f7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.2 Recommended Dosage and
Administration</title>
                     <text>
                        <paragraph>The recommended dosage, titration, and administration of phentermine and topiramate extended-release capsules are as follows:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Take phentermine and topiramate extended-release capsules orally once daily in the morning with or without food. Avoid administration of phentermine and topiramate extended-release capsules in the evening due to the possibility of insomnia.</item>
                           <item>The recommended starting dosage of phentermine and topiramate extended-release capsules is one capsule (containing 3.75 mg of phentermine and 23 mg of topiramate) (3.75 mg/23 mg) taken orally once daily for 14 days; after 14 days increase to the recommended dosage of phentermine and topiramate extended-release capsules 7.5 mg/46 mg orally once daily.</item>
                           <item>After 12 weeks of treatment with phentermine and topiramate extended-release capsules 7.5 mg/46 mg, evaluate weight loss for adults. If an adult patient has not lost at least 3% of baseline body weight, increase the dosage to phentermine and topiramate extended-release capsules 11.25 mg/69 mg orally once daily for 14 days; followed by an increase in the dosage to phentermine and topiramate extended-release capsules 15 mg/92 mg orally once daily.</item>
                           <item>After 12 weeks of treatment with phentermine and topiramate extended-release capsules 15 mg/92 mg, evaluate weight loss for adults. If an adult patient has not lost at least 5% of baseline body weight, discontinue phentermine and topiramate extended-release capsules <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">2.3</linkHtml>)]</content>, as it is unlikely that the patient will achieve and sustain clinically meaningful weight loss with continued treatment.</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">
                     <id root="cb5bce35-307f-4b71-aac4-faf435124c59"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.3 Discontinuation of Phentermine and Topiramate Extended-Release Capsules 15 mg/92 mg</title>
                     <text>
                        <paragraph>Discontinue phentermine and topiramate extended-release capsules 15 mg/92 mg gradually by taking phentermine and topiramate extended-release capsules 15 mg/92 mg orally once daily every other day for at least 1 week prior to stopping treatment altogether, due to the possibility of precipitating a seizure <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>) and Drug Abuse and Dependence (<linkHtml href="#www.splportal.comLINK_4a86212c-5ad9-48f1-8eae-da4a3b6fdb7e">9.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_364260b5-aa45-4a0a-a2a2-699a569736cd">
                     <id root="851368be-2f3c-4387-906f-10ec10c8a591"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.4 Recommended Dosage in
Patients with Renal Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage in patients with mild (CrCl greater or equal to 50 and less than 80 mL/min) renal impairment is the same as the recommended dosage for patients with normal renal function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>), Use in Specific Populations (<linkHtml href="#LINK_3cfe6707-f747-4c13-b703-c9392903a32a">8.6</linkHtml>), and Clinical Pharmacology (<linkHtml href="#LINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</item>
                           <item>In patients with severe [creatinine clearance (CrCl) less than 30 mL/min] or moderate (CrCl greater than or equal to 30 and less than 50 mL/min) renal impairment (CrCl calculated using the Cockcroft-Gault equation with actual body weight), the maximum recommended dosage is phentermine and topiramate extended-release capsules 7.5 mg/46 mg once daily.</item>
                           <item>Avoid use of phentermine and topiramate extended-release capsules in patients with end-stage renal disease on dialysis.</item>
                        </list>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_e02e7bff-ca62-45b3-b30f-b285776673af">
                     <id root="de2ac686-c4bf-43c5-9e96-2612fa2e3763"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>2.5 Recommended Dosage in
Patients with Hepatic Impairment</title>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>The recommended dosage of phentermine and topiramate extended-release capsules in patients with mild hepatic impairment (Child-Pugh 5 to 6) is the same as the recommended dosage in patients with normal hepatic function <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#LINK_4e00135e-f7b2-4351-834b-072e74f0f5a6">8.7</linkHtml>), and Clinical Pharmacology (<linkHtml href="#LINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</item>
                           <item>In patients with moderate hepatic impairment (Child-Pugh score 7 to 9), the maximum recommended dosage is phentermine and topiramate extended-release capsules 7.5 mg/46 mg orally once daily.</item>
                           <item>Avoid use of phentermine and topiramate extended-release capsules in patients with severe hepatic impairment (Child-Pugh score 10 to 15). </item>
                        </list>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">
               <id root="d9981859-7fad-45c0-be2b-e72110beb689"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Phentermine and topiramate extended-release capsules are available in four strengths (phentermine mg/topiramate mg):</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>3.75 mg/23 mg - White opaque cap printed with WPI, orange opaque body printed with 2196</item>
                     <item>7.5 mg/46 mg - White opaque cap printed with WPI, green opaque body printed with 2195</item>
                     <item>11.25 mg/69 mg - Light yellow opaque cap printed with WPI, white opaque body printed with 2299</item>
                     <item>15 mg/92 mg - White opaque cap printed with WPI, dark scarlet opaque body printed with 2194</item>
                  </list>
               </text>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Extended-release capsules: (phentermine mg/topiramate mg)</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>3.75 mg/23 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</item>
                           <item>7.5 mg/46 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</item>
                           <item>11.25 mg/69 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</item>
                           <item>15 mg/92 mg (<linkHtml href="#LINK_8d304253-ddc5-4f73-9e6b-a310c65ae429">3</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">
               <id root="762cd51f-c9ea-49a9-8cbe-7b5c69fdd557"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Phentermine and topiramate extended-release capsules are contraindicated in patients:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Who are pregnant <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>)]</content>
                     </item>
                     <item>With glaucoma <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_515ed8db-32ae-468b-8622-c54a0f4b8dfa">5.3</linkHtml>)]</content>
                     </item>
                     <item>With hyperthyroidism</item>
                     <item>Taking or within 14 days of stopping a monoamine oxidase inhibitors <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>
                     </item>
                     <item>With known hypersensitivity to phentermine, topiramate or any of the excipients inÂ phentermine and topiramate extended-release capsules, or idiosyncrasy to the sympathomimetic amines <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_f119b0a8-34eb-485a-94d1-57c8455f5360">6.2</linkHtml>)]</content>.</item>
                  </list>
               </text>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>Pregnancy (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                           <item>Glaucoma (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                           <item>Hyperthyroidism (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                           <item>Taking or within 14 days of stopping monoamine oxidase inhibitors (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                           <item>Known hypersensitivity to any component of phentermine and topiramate extended-release capsules or idiosyncrasy to sympathomimetic amines (<linkHtml href="#LINK_28e66f97-39e2-493a-bde5-03b3b8b399ba">4</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_5da03a55-6cf3-43ed-aa05-5b795a2fcf91">
               <id root="a9a4e5e8-214b-4691-af16-cee9aea47a18"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <text/>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Embryo-Fetal Toxicity:</content> Can cause fetal harm. In patients who can become pregnant, a negative pregnancy test is recommended before initiating phentermine and topiramate extended-release capsules and monthly during therapy; advise use of effective contraception. Phentermine and topiramate extended-release capsules are available through a limited program under a Risk Evaluation and Mitigation Strategy (REMS) (<linkHtml href="#LINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Suicidal Behavior and Ideation:</content> Monitor for depression or suicidal thoughts. Discontinue phentermine and topiramate extended-release capsules if symptoms develop (<linkHtml href="#LINK_88e905e2-0293-48df-99bc-a7b7ae095980">5.2</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Risk of Ophthalmologic Adverse Reactions:</content> Acute myopia and secondary angle closure glaucoma have been reported. Immediately discontinue phentermine and topiramate extended-release capsules if symptoms develop. Consider phentermine and topiramate extended-release capsules discontinuation if visual field defects occur (<linkHtml href="#LINK_515ed8db-32ae-468b-8622-c54a0f4b8dfa">5.3</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Mood and Sleep Disorders:</content> Consider dosage reduction or discontinuation for clinically significant or persistent mood or sleep disorder symptoms (<linkHtml href="#LINK_d1821dbd-fec3-47f4-a506-0ba68056ea48">5.4</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Cognitive Impairment:</content> May cause disturbances in attention or memory, or speech/language problems. Caution patients about operating automobiles or hazardous machinery when starting treatment (<linkHtml href="#LINK_9ad9259d-09a3-409b-9025-0739a026b9e1">5.5</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Slowing of Linear Growth:</content> Consider dosage reduction or discontinuation if pediatric patients are not growing or gaining height as expected (<linkHtml href="#LINK_f2ebdc9e-3271-4617-ab8c-f802d4b91688">5.6</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Metabolic Acidosis:</content> Measure electrolytes before and during treatment. If persistent metabolic acidosis develops, reduce dosage or discontinue phentermine and topiramate extended-release capsules (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Decrease in Renal Function:</content> Measure creatinine before and during treatment. For persistent creatinine elevations, reduce dosage or discontinue phentermine and topiramate extended-release capsules (<linkHtml href="#LINK_b180e995-2372-4766-8c58-f170b8da4e8b">5.8</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Serious Skin Reactions:</content> Phentermine and topiramate extended-release capsules should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related (<linkHtml href="#LINK_4a7235c0-3712-4670-83e8-525f3a849a72">5.13</linkHtml>).Â </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_074785d7-e224-4012-b5df-bd6ac6606c97">
                     <id root="5a020f07-b355-4b86-8b11-b4ac8bb39ccc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.1 Embryo-Fetal Toxicity</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause fetal harm. Data from pregnancy registries and epidemiologic studies indicate that a fetus exposed to topiramate in the first trimester of pregnancy has an increased risk of major congenital malformations, including but not limited to cleft lip and/or cleft palate (oral clefts), and of being small for gestational age (SGA). When multiple species of pregnant animals received topiramate at clinically relevant doses, structural malformations, including craniofacial defects, and reduced fetal weights occurred in offspring. A negative pregnancy test is recommended before initiating phentermine and topiramate extended-release capsule treatment in patients who can become pregnant and monthly during phentermine and topiramate extended-release capsule therapy. Advise patients who can become pregnant of the potential risk to a fetus and to use effective contraception during phentermine and topiramate extended-release capsule therapy <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>,Â <linkHtml href="#www.splportal.comLINK_c8d68c91-d39c-4861-a99b-63f774483a8d">8.3</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Phentermine and Topiramate Extended-Release Capsules <content styleCode="underline">Risk Evaluation and Mitigation Strategy (REMS)</content>
                           </content>
                        </paragraph>
                        <paragraph>Because of the teratogenic risk associated with phentermine and topiramate extended-release capsule therapy, phentermine and topiramate extended-release capsules are available through a limited program under the REMS. Under the Phentermine and Topiramate Extended-Release Capsules REMS, only certified pharmacies may distribute phentermine and topiramate extended-release capsules. Further information is available at www.PhenTopREMS.com or by telephone at 1-800-269-6816 or by FAX at 1-800-558-6165.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_88e905e2-0293-48df-99bc-a7b7ae095980">
                     <id root="923c0a91-f72e-4ebe-a7a5-d529cf6daec1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.2 Suicidal Behavior and
Ideation</title>
                     <text>
                        <paragraph>Antiepileptic drugs (AEDs), including topiramate, increase the risk of suicidal thoughts or behavior in patients taking these drugs for any indication. Pooled analyses of 199 placebo-controlled clinical studies (monotherapy and adjunctive therapy, median treatment duration 12 weeks) of 11 different AEDs across several indications showed that patients randomized to one of the AEDs had approximately twice the risk (adjusted Relative Risk 1.8, 95% CI 1.2, 2.7) of suicidal thinking or behavior compared to patients randomized to placebo. The estimated incidence rate of suicidal behavior or ideation among 27,863 AED-treated patients was 0.43%, compared to 0.24% among 16,029 placebo-treated patients, representing an increase of approximately one case of suicidal thinking or behavior for every 530 patients treated. There were four suicides in AED-treated patients in the trials and none in placebo-treated patients, but the number is too small to allow any conclusion about AED effect on suicide. The increased risk of suicidal thoughts or behavior with AEDs was observed as early as 1 week after starting drug treatment with AEDs and persisted for the duration of treatment assessed. Because most trials included in the analysis did not extend beyond 24 weeks, the risk of suicidal thoughts or behavior beyond 24 weeks could not be assessed. The risk of suicidal thoughts or behavior was generally consistent among drugs in the data analyzed. The finding of increased risk with AEDs of varying mechanisms of action and across a range of indications suggests that the risk applies to all AEDs used for any indication. The risk did not vary substantially by age in the clinical trials analyzed.</paragraph>
                        <paragraph>Monitor all patients for the emergence or worsening of depression, suicidal thoughts or behavior, and/or any unusual changes in mood or behavior. Discontinue phentermine and topiramate extended-release capsules in patients who experience suicidal thoughts or behaviors <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>. Avoid phentermine and topiramate extended-release capsules in patients with a history of suicidal attempts or active suicidal ideation.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_515ed8db-32ae-468b-8622-c54a0f4b8dfa">
                     <id root="3e905915-3a7c-4542-99ab-04e084426e42"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.3 Risk of Ophthalmologic Adverse Reactions</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Acute Myopia and Secondary Angle Closure Glaucoma</content>
                        </paragraph>
                        <paragraph>A syndrome consisting of acute myopia associated with secondary angle closure glaucoma has been reported in patients treated with topiramate. Symptoms include acute onset of decreased visual acuity and/or ocular pain. Ophthalmologic findings can include myopia, mydriasis, anterior chamber shallowing, ocular hyperemia (redness), choroidal detachments, retinal pigment epithelial detachments, macular striae, and increased intraocular pressure. This syndrome may be associated with supraciliary effusion resulting in anterior displacement of the lens and iris, with secondary angle closure glaucoma. Symptoms typically occur within 1 month of initiating treatment with topiramate but may occur at any time during therapy. In contrast to primary narrow angle glaucoma, which is rare under 40 years of age, secondary angle closure glaucoma associated with topiramate has been reported in pediatric patients as well as adults.Â The primary treatment to reverse symptoms is discontinuation of phentermine and topiramate extended-release capsules as rapidly as possible in consultation with the treating physician. Elevated intraocular pressure of any etiology, if left untreated, can lead to serious sequelae including permanent loss of vision.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Visual Field Defects</content>
                        </paragraph>
                        <paragraph>Visual field defects (independent of elevated intraocular pressure) have been reported in clinical trials and in postmarketing experience in patients receiving topiramate. In clinical trials, most of these events were reversible after topiramate discontinuation. If visual problems occur at any time during treatment, consider discontinuing phentermine and topiramate extended-release capsules.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_d1821dbd-fec3-47f4-a506-0ba68056ea48">
                     <id root="1a02ce6c-cc31-42ae-b3c0-c40cbdc48fad"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.4 Mood and Sleep Disorders</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause mood disorders, including depression and anxiety, as well as insomnia. Patients with a history of depression may be at increased risk of recurrent depression or other mood disorders while taking phentermine and topiramate extended-release capsules <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>Consider dosage reduction or discontinuation of phentermine and topiramate extended-release capsules if clinically significant or persistent symptoms occur. Discontinue phentermine and topiramate extended-release capsules if patients have symptoms of suicidal ideation or behavior <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_88e905e2-0293-48df-99bc-a7b7ae095980">5.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_9ad9259d-09a3-409b-9025-0739a026b9e1">
                     <id root="74018283-5065-43f2-a68e-c4debb20fb85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.5 Cognitive Impairment</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause cognitive dysfunction (e.g., impairment of concentration/attention, difficulty with memory, and speech or language problems, particularly word-finding difficulties). Rapid titration or high initial doses of phentermine and topiramate extended-release capsules may be associated with higher rates of cognitive events such as attention, memory, and language/word-finding difficulties <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>)]</content>. The concomitant use of alcohol or central nervous system (CNS) depressant drugs with phentermine and topiramate extended-release capsules may potentiate CNS depression or other centrally mediated effects of these agents, such as dizziness, cognitive adverse reactions, drowsiness, light-headedness, impaired coordination, and somnolence.</paragraph>
                        <paragraph>Caution patients about operating hazardous machinery, including automobiles, until they are reasonably certain phentermine and topiramate extended-release capsule therapy does not affect them adversely. Caution patients against excessive alcohol intake while receiving phentermine and topiramate extended-release capsules.</paragraph>
                        <paragraph>If cognitive dysfunction persists, consider dosage reduction or discontinuation of phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f2ebdc9e-3271-4617-ab8c-f802d4b91688">
                     <id root="13d708f8-1f1d-4861-9e10-ce7f3d1fbcb4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.6 Slowing of Linear
Growth</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules are associated with a reduction in height velocity (centimeters of height gained per year) in obese pediatric patients. Monitor height velocity in pediatric patients treated with phentermine and topiramate extended-release capsules. Consider dosage reduction or discontinuation of phentermine and topiramate extended-release capsules if pediatric patients are not growing or gaining height as expected <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">
                     <id root="48259ba8-e7e8-4105-924f-ad95eaedc82d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.7 Metabolic Acidosis</title>
                     <text>
                        <paragraph>Hyperchloremic, non-anion gap, metabolic acidosis (decreased serum bicarbonate below the normal reference range in the absence of chronic respiratory alkalosis) has been reported in patients treated with phentermine and topiramate extended-release capsules <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>)]</content>. Manifestations of acute or chronic metabolic acidosis may include hyperventilation, nonspecific symptoms such as fatigue and anorexia, or more severe sequelae including cardiac arrhythmias or stupor. Chronic, untreated metabolic acidosis may increase the risk for nephrolithiasis or nephrocalcinosis and may also result in osteomalacia (referred to as rickets in pediatric patients) and/or osteoporosis with an increased risk for fractures. Chronic metabolic acidosis in pediatric patients may also reduce growth rates, which may decrease the maximal height achieved.Â </paragraph>
                        <paragraph>Conditions or therapies that predispose to acidosis (i.e., renal disease, severe respiratory disorders, status epilepticus, diarrhea, surgery, or ketogenic diet) may be additive to the bicarbonate lowering effects of phentermine and topiramate extended-release capsules. Concomitant use of phentermine and topiramate extended-release capsules and a carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_5da57159-b1c5-4f5c-8e81-da62441b9205">5.10</linkHtml>)]</content>. Avoid use of phentermine and topiramate extended-release capsules with other carbonic anhydrase inhibitors. If concomitant use of phentermine and topiramate extended-release capsules with another carbonic anhydrase inhibitor is unavoidable, the patient should be monitored for the appearance or worsening of metabolic acidosis.</paragraph>
                        <paragraph>Measure electrolytes including serum bicarbonate prior to starting phentermine and topiramate extended-release capsules and during phentermine and topiramate extended-release capsule treatment. In phentermine and topiramate extended-release capsule clinical trials, the peak reduction in serum bicarbonate typically occurred within 4 weeks of titration to the assigned dose, and in most patients, there was a correction of bicarbonate by week 56, without any dosage reduction. However, if persistent metabolic acidosis develops while taking phentermine and topiramate extended-release capsules, reduce the dosage or discontinue phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.</linkHtml>
                              <linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">9</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_b180e995-2372-4766-8c58-f170b8da4e8b">
                     <id root="68514cc4-fbaf-4c11-a2f4-1c4badaa0828"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.8 Decrease in Renal Function</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause an increase in serum creatinine that reflects a decrease in renal function (glomerular filtration rate). In clinical trials, peak increases in serum creatinine were observed after 4 to 8 weeks of treatment. On average, serum creatinine gradually declined but remained elevated over baseline creatinine values. The changes in serum creatinine (and measured GFR) with short-term (4-weeks) phentermine and topiramate extended-release capsule treatment appear reversible with treatment discontinuation, but the effect of chronic treatment on renal function is not known.</paragraph>
                        <paragraph>Measure serum creatinine prior to starting phentermine and topiramate extended-release capsules and during phentermine and topiramate extended-release capsule treatment. If persistent elevations in creatinine occur, reduce the dosage or discontinue phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>), Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>), and Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_6bed2f55-21d1-4f92-8d05-cea5c21add2b">12.2</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">
                     <id root="9f181888-de15-4e2d-aaeb-203a888b3801"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.9 Risk of Seizures with
Abrupt Withdrawal of Phentermine and Topiramate
Extended-Release Capsules</title>
                     <text>
                        <paragraph>Abrupt withdrawal of topiramate has been associated with seizures in individuals without a history of seizures or epilepsy. In situations where immediate termination of phentermine and topiramate extended-release capsules is medically required, appropriate monitoring is recommended. Patients discontinuing phentermine and topiramate extended-release capsules 15 mg/92 mg should be gradually tapered to reduce the possibility of precipitating a seizure <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">2.3</linkHtml>) and Drug Abuse and Dependence (<linkHtml href="#www.splportal.comLINK_4a86212c-5ad9-48f1-8eae-da4a3b6fdb7e">9.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_5da57159-b1c5-4f5c-8e81-da62441b9205">
                     <id root="58ce4fc1-9d2d-4684-8c92-ffe20cc5eefc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.10 Kidney Stones</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules have been associated with kidney stone formation <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>)]</content>. Topiramate inhibits carbonic anhydrase activity and promotes kidney stone formation by reducing urinary citrate excretion and increasing urine pH. Patients on a ketogenic diet may be at increased risk for kidney stone formation. An increase in urinary calcium and a marked decrease in urinary citrate was observed in topiramate-treated pediatric patients in a one-year, active-controlled study.Â Increased ratio of urinary calcium/citrate increases the risk of kidney stones and/or nephrocalcinosis.</paragraph>
                        <paragraph>Avoid the use of phentermine and topiramate extended-release capsules with other drugs that inhibit carbonic anhydrase <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>. Advise patients to increase fluid intake (to increase urinary output), which may decrease the concentration of substances involved in kidney stone formation.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_29349ff4-26fe-4ca4-86e3-17d65cda63ff">
                     <id root="4986a036-9a3f-4679-ac67-1469e0612421"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.11 Oligohidrosis and
Hyperthermia</title>
                     <text>
                        <paragraph>Oligohidrosis (decreased sweating), infrequently resulting in hospitalization, has been reported in association with the use of topiramate. Decreased sweating and an elevation in body temperature above normal characterized these cases. Some of the cases have been reported with topiramate after exposure to elevated environmental temperatures.</paragraph>
                        <paragraph>The majority of the reports associated with topiramate have been in pediatric patients.Â Advise all patients and caregivers to monitor for decreased sweating and increased body temperature during physical activity, especially in hot weather. Patients on concomitant medications that predispose them to heat-related disorders may be at increased risk.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_7850101b-a9e8-41ed-b234-615c1f24fc79">
                     <id root="4d11b7c1-ed8c-4d93-97ed-d2ad729dcf1b"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.12 Hypokalemia</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules can increase the risk of hypokalemia through its inhibition of carbonic anhydrase activity. In addition, when phentermine and topiramate extended-release capsules are used in conjunction with non-potassium sparing diuretics this may further potentiate potassium-wasting. Measure potassium before and during treatment with phentermine and topiramate extended-release capsules <content styleCode="italics">[see Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>), Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>), and Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4a7235c0-3712-4670-83e8-525f3a849a72">
                     <id root="65327fb7-a31d-47bb-a863-533d8d4985ce"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>5.13 Serious Skin Reactions</title>
                     <text>
                        <paragraph>Serious skin reactions (Stevens-Johnson Syndrome [SJS] and Toxic Epidermal Necrolysis [TEN]) have been reported in patients receiving topiramate. Phentermine and topiramate extended-release capsules should be discontinued at the first sign of a rash, unless the rash is clearly not drug-related. If signs or symptoms suggest SJS/TEN, use of this drug should not be resumed, and alternative therapy should be considered. Inform patients about the signs of serious skin reactions.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_0178f8ac-a85d-403a-aa95-816dd29368aa">
               <id root="027f91fd-49a4-4a4f-b582-e7f29f07fc97"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following clinically significantÂ adverse reactions are described elsewhere in the labeling:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Embryo-Fetal Toxicity <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>, <linkHtml href="#www.splportal.comLINK_3cfe6707-f747-4c13-b703-c9392903a32a">8.6</linkHtml>)]</content>
                     </item>
                     <item>Suicidal Behavior and Ideation <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_88e905e2-0293-48df-99bc-a7b7ae095980">5.2</linkHtml>)]</content>
                     </item>
                     <item>Risk of Ophthalmologic Adverse Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_515ed8db-32ae-468b-8622-c54a0f4b8dfa">5.3</linkHtml>)]</content>
                     </item>
                     <item>Mood and Sleep Disorders <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_d1821dbd-fec3-47f4-a506-0ba68056ea48">5.4</linkHtml>)]</content>
                     </item>
                     <item>Cognitive Impairment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_9ad9259d-09a3-409b-9025-0739a026b9e1">5.5</linkHtml>)]</content>
                     </item>
                     <item>Slowing of Linear Growth<content styleCode="italics"> [see Warnings and Precautions (<linkHtml href="#LINK_f2ebdc9e-3271-4617-ab8c-f802d4b91688">5.6</linkHtml>)]</content>
                     </item>
                     <item>Metabolic Acidosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>)]</content>
                     </item>
                     <item>Decrease in Renal Function <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b180e995-2372-4766-8c58-f170b8da4e8b">5.8</linkHtml>)]</content>
                     </item>
                     <item>Risk of Seizures with Abrupt Withdrawal of Phentermine and Topiramate Extended-Release Capsules <content styleCode="italics">[see Warnings and Precautions <linkHtml href="#www.splportal.comLINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">(</linkHtml>
                           <linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>
                     </item>
                     <item>Kidney Stones <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_5da57159-b1c5-4f5c-8e81-da62441b9205">5.10</linkHtml>)]</content>
                     </item>
                     <item>Oligohidrosis and Hyperthermia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_29349ff4-26fe-4ca4-86e3-17d65cda63ff">5.11</linkHtml>)]</content>
                     </item>
                     <item>Hypokalemia <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_7850101b-a9e8-41ed-b234-615c1f24fc79">5.12</linkHtml>)]</content>
                     </item>
                     <item>Serious Skin Reactions <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4a7235c0-3712-4670-83e8-525f3a849a72">5.13</linkHtml>)]</content>
                     </item>
                  </list>
               </text>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Most common adverse reactions in:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>Adults (incidence â¥ 5% and at least 1.5 times placebo) are: paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth (<linkHtml href="#LINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>).</item>
                        </list>
                        <paragraph>
                           <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Teva at 1-888-838-2872 or FDA at 1-800-FDA-1088 or <content styleCode="italics">www.fda.gov/medwatch</content>.</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="bold">Â </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">
                     <id root="1f663b5e-2145-489c-a370-78ad8bcb1ad1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.1 Clinical Trials Experience</title>
                     <text>
                        <paragraph>Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical studies of another drug and may not reflect the rates observed in practice.</paragraph>
                        <paragraph>The data described herein reflect exposure to phentermine and topiramate extended-release capsules in two <br/>
1-year, randomized, double-blind, placebo-controlled, multicenter clinical trials and two supportive trials in 2,318 adult patients with overweight or obesity [936 (40%) patients with hypertension, 309 (13%) patients with type 2 diabetes mellitus, 808 (35%) patients with BMI greater than 40 kg/m<sup>2</sup>] exposed for a mean duration of 298 days <content styleCode="italics">[see Clinical Studies (<linkHtml href="#www.splportal.comLINK_3b3b30e3-796c-4f9e-9835-f7ecffe4ccf2">14</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Adults</content>
                        </paragraph>
                        <paragraph>Adverse reactions occurring at greater than or equal to 5% and at least 1.5 times placebo in adults include paraesthesia, dizziness, dysgeusia, insomnia, constipation, and dry mouth.</paragraph>
                        <paragraph>Adverse reactions reported in greater than or equal to 2% of phentermine and topiramate extended-release capsule-treated adults and more frequently than in the placebo group are shown in Table 1.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 1. Adverse Reactions Reported in â¥2% of Phentermine and Topiramate Extended-Release Capsule-Treated Adults with Overweight or Obesity and More Frequently than Placebo in Overall Study Population of 1 Year Duration</caption>
                           <col width="211.75pt"/>
                           <col width="74.95pt"/>
                           <col width="82.7pt"/>
                           <col width="78.7pt"/>
                           <col width="78.9pt"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>
            Placebo<br/>
                                       </content>
                                       <content styleCode="bold">(N = 1,561)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">3.75 mg/23 mg<br/>
                                       </content>
                                       <content styleCode="bold">(N = 240)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">7.5 mg/46 mg<br/>
                                       </content>
                                       <content styleCode="bold">(N = 498)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">15 mg/92 mg<br/>
                                       </content>
                                       <content styleCode="bold">(N = 1,580)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Adverse Reaction</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">%</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Paraesthesia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>20</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dry Mouth</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>19</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Constipation</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>16</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Upper Respiratory Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>16</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>12</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>14</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Headache</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>10</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>11</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dysgeusia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Insomnia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nasopharyngitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>13</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>11</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dizziness</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>9</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Sinusitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nausea</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Back Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Fatigue</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Diarrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Vision Blurred</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>6</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Bronchitis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>7</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Urinary Tract Infection</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Cough</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Influenza</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>8</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>5</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Depression</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Anxiety</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypoesthesia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Irritability</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Alopecia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Disturbance in Attention</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>4</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pain in Extremity</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Muscle Spasms</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dyspepsia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Gastroesophageal Reflux Disease</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Rash</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Hypokalemia</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dry Eye</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Gastroenteritis</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Pharyngolaryngeal Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Paraesthesia Oral</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Eye Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Nasal Congestion</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Thirst</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Sinus Congestion</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Procedural Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Palpitations</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Musculoskeletal Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>3</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Decreased Appetite</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Neck Pain</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Dysmenorrhea</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Chest Discomfort</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>2</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>0</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Increase in Heart Rate</content>
                        </paragraph>
                        <paragraph>In adult clinical trials, there was a higher incidence of heart rate elevations observed in phentermine and topiramate extended-release capsule-treated compared to placebo-treated patients.</paragraph>
                        <paragraph>Table 3 provides the numbers and percentages of adult patients with elevations in heart rate in clinical studies of up to one year.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 3. Number and Percentage of Adults with Overweight or Obesity with an Increase in Heart Rate at a Single Time Point from Baseline</caption>
                           <col width="119.55pt"/>
                           <col width="80.3pt"/>
                           <col width="112.75pt"/>
                           <col width="112.75pt"/>
                           <col width="112.75pt"/>
                           <tbody>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">
                                          <br/>
            Placebo<br/>
                                       </content>
                                       <content styleCode="bold">N=1,561<br/>
                                       </content>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">3.75 mg/23 mg<br/>
                                       </content>
                                       <content styleCode="bold">N=240<br/>
                                       </content>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">7.5 mg/46 mg<br/>
                                       </content>
                                       <content styleCode="bold">N=498<br/>
                                       </content>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                       </content>
                                       <content styleCode="bold">15 mg/92 mg<br/>
                                       </content>
                                       <content styleCode="bold">N=1,580<br/>
                                       </content>
                                       <content styleCode="bold">n (%)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 5 bpm</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1021 (65.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>168 (70.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>372 (74.7)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>1228 (77.7)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 10 bpm</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>657 (42.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>120 (50.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>251 (50.4)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>887 (56.1)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 15 bpm</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>410 (26.3)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>79 (32.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>165 (33.1)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>590 (37.3)</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Greater than 20 bpm</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>186 (11.9)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>36 (15.0)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>67 (13.5)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>309 (19.6)</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="underline">Paraesthesia/Dysgeusia</content>
                        </paragraph>
                        <paragraph>In adult clinical trials, reports of paraesthesia, characterized as tingling in hands, feet, or face, and dysgeusia, characterized as a metallic taste, occurred (see Table 1). Phentermine and topiramate extended-release capsule-treated adult patients discontinued treatment due to these adverse reactions (1% for paraesthesia and 0.6% for dysgeusia).</paragraph>
                        <paragraph>
                           <content styleCode="underline">Mood and Sleep Disorders</content>
                        </paragraph>
                        <paragraph>The proportion of adult patients in 1-year controlled trials of phentermine and topiramate extended-release capsules reporting one or more adverse reactions related to mood and sleep disorders was 15% and 21% with phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 15 mg/92 mg, respectively, compared to 10% with placebo. These events were further categorized into sleep disorders, anxiety, and depression. Reports of sleep disorders were typically characterized as insomnia and occurred in 8.1% and 11% of patients treated with phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 15 mg/92 mg, respectively, compared to 5.8% of patients treated with placebo. Reports of anxiety occurred in 4.8% and 7.9% of patients treated with phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 15 mg/92 mg, respectively, compared to 2.6% of patients treated with placebo.</paragraph>
                        <paragraph>Reports of depression/mood problems occurred in 3.8% and 7.6% of patients treated with phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 15 mg/92 mg, respectively, compared to 3.4% of patients treated with placebo. Mood and sleep disorder adverse reactions occurred in patients with and without a history of depression.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cognitive Disorders</content>
                        </paragraph>
                        <paragraph>In the 1-year controlled trials of phentermine and topiramate extended-release capsules in adults, the proportion of patients who experienced one or more cognitive-related adverse reactions was 5.0% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 7.6% for phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 1.5% for placebo. These adverse reactions were comprised primarily of reports of problems with attention/concentration, memory, and language (word-finding). These events occurred at any time during treatment with phentermine and topiramate extended-release capsules.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Nephrolithiasis</content>
                        </paragraph>
                        <paragraph>In the 1-year controlled trials of phentermine and topiramate extended-release capsules in adults, the incidence of nephrolithiasis was 0.2% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 1.2% for phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 0.3% for placebo.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Laboratory Abnormalities</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Serum Bicarbonate</content>
                        </paragraph>
                        <paragraph>In the 1-year controlled trials of phentermine and topiramate extended-release capsules in adults, the incidence of persistent decreases in serum bicarbonate below the normal range (levels of less than 21 mEq/L at 2 consecutive visits or at the final visit) was 6.4% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 12.8% for phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 2.1% for placebo. The incidence of persistent, markedly low serum bicarbonate values (levels of less than 17 mEq/L on 2 consecutive visits or at the final visit) was 0.2% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg dose and 0.7% for phentermine and topiramate extended-release capsules 15 mg/92 mg dose, compared to 0.1% for placebo. </paragraph>
                        <paragraph>
                           <content styleCode="italics">Serum Potassium</content>
                        </paragraph>
                        <paragraph>In the 1-year controlled trials of phentermine and topiramate extended-release capsules in adults, the incidence of persistent low serum potassium values (less than 3.5 mEq/L at two consecutive visits or at the final visit) during the trial was 3.6% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg dose and 4.9% for phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 1.1% for placebo. Of the subjects who experienced persistent low serum potassium, 88% were receiving treatment with a non-potassium sparing diuretic.</paragraph>
                        <paragraph>The incidence of markedly low serum potassium (less than 3 mEq/L, and a reduction from pre-treatment of greater than 0.5 mEq/L) at any time during the trial was 0.2% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg dose and 0.7% for phentermine and topiramate extended-release capsules 15 mg/92 mg dose, compared to 0.0% for placebo. Persistent markedly low serum potassium (less than 3 mEq/L, and a reduction from pre-treatment of greater than 0.5 mEq/L at two consecutive visits or at the final visit) occurred in 0.2% receiving phentermine and topiramate extended-release capsules 7.5 mg/46 mg dose and 0.1% receiving phentermine and topiramate extended-release capsules 15 mg/92 mg dose, compared to 0.0% receiving placebo.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Serum Creatinine</content>
                        </paragraph>
                        <paragraph>In the 1-year controlled trials of phentermine and topiramate extended-release capsules in adults, there was an increase in serum creatinine from baseline, peaking between Week 4 to 8 in adult patients. Serum creatinine values declined but remained elevated over baseline over 1 year of treatment. The incidence of increases in serum creatinine of greater than or equal to 0.3 mg/dL at any time during treatment in adults was 7.2% for phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 8.4% for phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 2.0% for placebo. Increases in serum creatinine of greater than or equal to 50% over baseline occurred in 2.0% of adult subjects receiving phentermine and topiramate extended-release capsules 7.5 mg/46 mg and 2.8% receiving phentermine and topiramate extended-release capsules 15 mg/92 mg, compared to 0.6% receiving placebo.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Serum Ammonia</content>
                        </paragraph>
                        <paragraph>Hyperammonemia with or without encephalopathy has been reported with topiramate. The risk for hyperammonemia with topiramate appears dose related and has been reported more frequently when concomitantly used with valproic acid <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>The incidence of hyperammonemia in pediatric patients 12 to 17 years of age in clinical trials of another condition was 26% in patients taking topiramate at 100 mg/day (1.1 times the maximum recommended dosage of phentermine and topiramate extended-release capsules) and 14% in patients taking topiramate at 50 mg/day (0.6 times the maximum recommended dosage of phentermine and topiramate extended-release capsules), compared to 9% in patients taking placebo. There was also an increased incidence of markedly increased hyperammonemia (defined as 50% above the upper limit of normal reference range) at the 100 mg dose.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_f119b0a8-34eb-485a-94d1-57c8455f5360">
                     <id root="e76e07fc-3c22-4f0d-962d-facc9fb3c133"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>6.2 Postmarketing Experience</title>
                     <text>
                        <paragraph>The following adverse reactions have been reported during post approval use of phentermine and topiramate extended-release capsules, phentermine, and topiramate. Because these reactions are reported voluntarily from a population of uncertain size it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Phentermine and Topiramate Extended-Release Capsules</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Psychiatric:</content> suicidal ideation, suicidal behavior</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ophthalmic:</content> acute angle closure glaucoma, increased intraocular pressure </paragraph>
                        <paragraph>
                           <content styleCode="underline">Phentermine</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Allergic Reactions:</content> urticaria</paragraph>
                        <paragraph>
                           <content styleCode="italics">Cardiovascular:</content> elevation of blood pressure, ischemic events </paragraph>
                        <paragraph>
                           <content styleCode="italics">Central Nervous System:</content> euphoria, psychosis, tremor </paragraph>
                        <paragraph>
                           <content styleCode="italics">Reproductive:</content> changes in libido, impotence</paragraph>
                        <paragraph>
                           <content styleCode="underline">Topiramate</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Dermatologic:</content> bullous skin reactions (including erythema multiforme, Stevens-Johnson syndrome, toxic epidermal necrolysis), pemphigus</paragraph>
                        <paragraph>
                           <content styleCode="italics">Gastrointestinal:</content> pancreatitis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hepatic:</content> hepatic failure (including fatalities), hepatitis</paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolic:</content> hyperammonemia with or without encephalopathy has been reported with concomitant valproic acid <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>, hypothermia</paragraph>
                        <paragraph>
                           <content styleCode="italics">Ophthalmic:</content> maculopathy</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">
               <id root="88ec0374-618f-49a2-8e5e-0e415e66cba2"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <text>
                  <paragraph>Table 5 displays clinically significant drug interactions with phentermine and topiramate extended-release capsules.</paragraph>
                  <table width="1000px" cellspacing="0" cellpadding="5">
                     <caption>Table 5. Clinically Significant Drug Interactions with Phentermine and Topiramate Extended-Release Capsules</caption>
                     <col width="94.3px"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Monoamine Oxidase Inhibitors</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Concomitant use of phentermine with monoamine oxidase inhibitors (MAOIs) increases the risk of hypertensive crisis.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Concomitant use of phentermine and topiramate extended-release capsules is contraindicated during MAOI treatment and within 14 days of stopping an MAOI.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Oral Contraceptives</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Coadministration of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily with a single dose of oral contraceptive containing 35 mcg ethinyl estradiol (estrogen component) and 1 mg norethindrone (progestin component), in obese otherwise healthy volunteers, decreased the exposure of ethinyl estradiol by 16% and increased the exposure of norethindrone by 22% <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>. Although this interaction is not anticipated to increase the risk of pregnancy, irregular bleeding (spotting) may occur more frequently due to both the increased exposure to the progestin and lower exposure to the estrogen, which tends to stabilize the endometrium.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Inform patients not to discontinue their combination oral contraceptive if spotting occurs, but to notify their health care provider if the spotting is troubling to them.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">CNS Depressants Including Alcohol</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>The concomitant use of alcohol or CNS depressant drugs (e.g., barbiturates, benzodiazepines, and sleep medications) with phentermine or topiramate may potentiate CNS depression such as dizziness or cognitive adverse reactions, or other centrally mediated effects of these agents.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Advise patients not to drive or operate machinery until they have gained sufficient experience on phentermine and topiramate extended-release capsules to gauge whether it adversely affects their mental performance, motor performance, and/or vision. Caution patients against excessive alcohol intake when taking phentermine and topiramate extended-release capsules. Consider phentermine and topiramate extended-release capsule dosage reduction or discontinuation if cognitive dysfunction persists <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_9ad9259d-09a3-409b-9025-0739a026b9e1">5.5</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Non-Potassium Sparing Diuretics</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Concurrent use of phentermine and topiramate extended-release capsules with non-potassium sparing diuretics may potentiate the potassium-wasting action of these diuretics. Concomitant administration of hydrochlorothiazide alone with topiramate alone has been shown to increase the C<sub>max</sub> and AUC of topiramate by 27% and 29%, respectively.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>When phentermine and topiramate extended-release capsules are used concomitantly with non-potassium-sparing diuretics, measure potassium before and during phentermine and topiramate extended-release capsule treatment <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_7850101b-a9e8-41ed-b234-615c1f24fc79">5.12</linkHtml>) and Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Antiepileptic Drugs</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Concomitant administration of phenytoin or carbamazepine with topiramate in patients with epilepsy, decreased plasma concentrations of topiramate by 48% and 40%, respectively, when compared to topiramate given alone <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>. Concomitant administration of valproic acid and topiramate has been associated with hyperammonemia with and without encephalopathy. Concomitant administration of topiramate with valproic acid in patients has also been associated with hypothermia (with and without hyperammonemia).</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Consider measuring blood ammonia in patients in whom the onset of hypothermia or encephalopathy has been reported <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Carbonic Anhydrase Inhibitors</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Concomitant use of topiramate with any other carbonic anhydrase inhibitor may increase the severity of metabolic acidosis and may also increase the risk of kidney stone formation.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Avoid the use of phentermine and topiramate extended-release capsules with other drugs that inhibit carbonic anhydrase. If concomitant use of phentermine and topiramate extended-release capsules with another carbonic anhydrase inhibitor is unavoidable, monitor patient for the appearance or worsening of metabolic acidosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>, <linkHtml href="#LINK_5da57159-b1c5-4f5c-8e81-da62441b9205">5.10</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Pioglitazone</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>A decrease in the exposure of pioglitazone and its active metabolites were noted with the concurrent use of pioglitazone and topiramate in a clinical trial. The clinical relevance of these observations is unknown.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Consider increased glycemic monitoring when using pioglitazone and phentermine and topiramate extended-release capsules concomitantly <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Amitriptyline</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Clinical Impact</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Some patients may experience a large increase in amitriptyline concentration in the presence of topiramate.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="right" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="italics">Intervention</content>
                              </paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Any adjustments in amitriptyline dose when used with phentermine and topiramate extended-release capsules should be made according to the patient's clinical response and not on the basis of amitriptyline levels <content styleCode="italics">[see Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
               </text>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Oral Contraceptives:</content> Altered exposure of progestin and estrogen may cause irregular bleeding, but not increased risk of pregnancy. Advise patients not to discontinue oral contraceptives if spotting occurs (<linkHtml href="#LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">CNS Depressants Including Alcohol:</content> May potentiate CNS depressant effects. Avoid excessive use of alcohol (<linkHtml href="#LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>).</item>
                           <item>
                              <content styleCode="italics">Non-potassium Sparing Diuretics:</content> May potentiate hypokalemia. Measure potassium before and during treatment (<linkHtml href="#LINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>).</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="LINK_28761c98-8bbc-4b25-802b-2f81d5f044d1">
               <id root="511f9cdd-5181-4342-80f2-3a98b3ea5b57"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <text/>
               <effectiveTime value="20241212"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="Disc">
                           <item>
                              <content styleCode="italics">Lactation:</content> Breastfeeding not recommended (<linkHtml href="#LINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">8.2</linkHtml>).</item>
                        </list>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                              <br/>
                              <br/>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="LINK_9db656bc-75ac-43c9-a8ea-adf611a00791">
                     <id root="bb0e6e8b-9f1a-4b81-a746-f0e1a423c181"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules are contraindicated in pregnant patients. The use of phentermine and topiramate extended-release capsules can cause fetal harm, and weight loss offers no clear clinical benefit to a pregnant patient <content styleCode="italics">(see Clinical Considerations)</content>. Available data from pregnancy registries and epidemiologic studies indicate an increased risk of major congenital malformations, including but not limited to cleft lip and/or cleft palate (oral clefts), and of being SGA in infants exposed <content styleCode="italics">in utero</content> to topiramate <content styleCode="italics">(see Data)</content>. When phentermine and topiramate were coadministered to rats at doses of 3.75 and 25 mg/kg, respectively [approximately 2 times the maximum recommended human dose (MRHD) based on area under the curve (AUC)], or at the same dose to rabbits (approximately 0.1 times and 1 time, respectively, the clinical exposures at the MRHD based on AUC), there were no drug-related malformations. However, structural malformations, including craniofacial defects and reduced fetal weights occurred in offspring of multiple species of pregnant animals administered topiramate at clinically relevant doses <content styleCode="italics">(see Data)</content>. Advise pregnant women of the potential risk to a fetus.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Disease Associated Maternal and/or Embryo/Fetal Risk</content>
                        </paragraph>
                        <paragraph>Weight loss during pregnancy may result in fetal harm. Appropriate weight gain based on pre-pregnancy weight is currently recommended for all pregnant patients, including those who are already overweight or obese, due to the obligatory weight gain that occurs in maternal tissues during pregnancy. Maternal obesity increases the risk for congenital malformations, including neural tube defects, cardiac malformations, oral clefts, and limb reduction defects.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Fetal/Neonatal Adverse Reactions</content>
                        </paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause metabolic acidosis <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>)]</content>. The effect of topiramate-induced metabolic acidosis has not been studied in pregnancy; however, metabolic acidosis in pregnancy (due to other causes) can cause decreased fetal growth, decreased fetal oxygenation, and fetal death, and may affect the fetusâ ability to tolerate labor.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Human Data</content>
                        </paragraph>
                        <paragraph>Data evaluating the risk of major congenital malformations, oral clefts, and being SGA with topiramate exposure during pregnancy is available from the North American Antiepileptic Drug (NAAED) Pregnancy Registry and from several larger retrospective epidemiologic studies. </paragraph>
                        <paragraph>Major Congenital Malformations</paragraph>
                        <paragraph>The NAAED Pregnancy Registry indicates an increased risk of major congenital malformations, including but not limited to oral clefts in infants exposed to topiramate during the first trimester of pregnancy. Other than oral clefts, no specific pattern of major congenital malformations or grouping of major congenital malformation types were observed. In the NAAED pregnancy registry, when topiramate-exposed infants with only oral clefts were excluded, the prevalence of major congenital malformations (4.1%) was higher than that in infants exposed to a reference antiepileptic drug (AED) (1.8%) or in infants with mothers without epilepsy and without exposure to AEDs (1.1%).</paragraph>
                        <paragraph>Oral Clefts</paragraph>
                        <paragraph>In the NAAED Pregnancy Registry, the prevalence of oral clefts among topiramate-exposed infants (1.4%) was higher than the prevalence in infants exposed to a reference AED (0.3%) or the prevalence in infants with mothers without epilepsy and without exposure to AEDs (0.11%). It was also higher than the background prevalence in United States (0.17%) as estimated by the Centers for Disease Control and Prevention (CDC). The relative risk of oral clefts in topiramate-exposed pregnancies in the NAAED Pregnancy Registry was 12.5 (95% Confidence Interval [CI] 5.9 to 26.37) as compared to the risk in a background population of untreated women. The UK Epilepsy and Pregnancy Register reported a prevalence of oral clefts among infants exposed to topiramate monotherapy (3.2%) that was 16 times higher than the background rate in the UK (0.2%).</paragraph>
                        <paragraph>Larger retrospective epidemiology studies showed that topiramate monotherapy exposure in pregnancy is associated with an approximately two to five-fold increased risk of oral clefts. The FORTRESS study found an excess risk of 1.5 (95% CI = -1.1 to 4.1) oral cleft cases per 1,000 infants exposed to topiramate during the first trimester.</paragraph>
                        <paragraph>Small for Gestational Age</paragraph>
                        <paragraph>Data from the NAAED Pregnancy Registry and population-based birth registry cohort indicate that exposure to topiramate <content styleCode="italics">in utero</content> is associated with an increased risk of SGA newborns (birth weight &lt;10<sup>th</sup> percentile). In the NAAED Pregnancy Registry, 19.7% of topiramate-exposed newborns were SGA compared to 7.9% of newborns exposed to a reference AED and 5.4% of newborns of mothers without epilepsy and without AED exposure. In the medical Birth Registry of Norway, a population-based pregnancy registry, 25% of newborns in the topiramate monotherapy exposure group were SGA compared to 9% in the comparison group unexposed to AEDs. The long-term consequences of the SGA findings are not known.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Animal Data</content>
                        </paragraph>
                        <paragraph>Phentermine/Topiramate</paragraph>
                        <paragraph>Embryo-fetal development studies have been conducted in rats and rabbits with combination phentermine and topiramate treatment. Phentermine and topiramate coadministered to rats during the period of organogenesis (gestation day (GD) 6 through 17) caused reduced fetal body weights but did not cause fetal malformations at the maximum dose of 3.75 mg/kg phentermine and 25 mg/kg topiramate [approximately 2 times the maximum recommended human dose (MRHD) based on area under the curve (AUC) estimates for each active ingredient]. In a similar study in rabbits in which the same doses were administered from GD 6 through 18, no effects on embryo-fetal development were observed at approximately 0.1 times (phentermine) and 1 time (topiramate) clinical exposures at the MRHD based on AUC. Significantly lower maternal body weight gain was recorded at these doses in rats and rabbits.</paragraph>
                        <paragraph>A pre- and post-natal development study was conducted in rats with combination phentermine and topiramate treatment. There were no adverse maternal or offspring effects in rats treated throughout organogenesis and lactation with 1.5 mg/kg/day phentermine and 10 mg/kg/day topiramate (approximately 2- and 3-times clinical exposures at the MRHD, respectively, based on AUC). Treatment with higher doses of 11.25 mg/kg/day phentermine and 75 mg/kg/day topiramate (approximately 5 and 6 times maximum clinical doses based on AUC, respectively) caused reduced maternal body weight gain and offspring toxicity. Offspring effects included lower pup survival after birth, increased limb and tail malformations, reduced pup body weight and delayed growth, development, and sexual maturation without affecting learning, memory, or fertility and reproduction. The limb and tail malformations were consistent with results of animal studies conducted with topiramate alone.</paragraph>
                        <paragraph>Phentermine</paragraph>
                        <paragraph>Animal reproduction studies have not been conducted with phentermine. Limited data from studies conducted with the phentermine/topiramate combination indicate that phentermine alone was not teratogenic but resulted in lower body weight and reduced survival of offspring in rats at 5-fold the MRHD of phentermine and topiramate extended-release capsules, based on AUC.</paragraph>
                        <paragraph>Topiramate</paragraph>
                        <paragraph>Topiramate causes developmental toxicity, including teratogenicity, at clinically relevant doses in multiple animal species.</paragraph>
                        <paragraph>Developmental toxicity, including teratogenicity, occurred at clinically relevant doses in multiple animal species in which topiramate was administered during the period of organogenesis (GD 6 to 15 in rodents, GD 6 to 18 in rabbits. In these studies, fetal malformations (primarily craniofacial defects such as cleft palate), limb malformations (ectrodactyly, micromelia, and amelia), rib/vertebral column anomalies, and/or reduced fetal weights were observed at dosages â¥ 20 mg/kg in mice (approximately 2 times the MRHD of topiramate in phentermine and topiramate extended-release capsules 15 mg/92 mg on a mg/m<sup>2</sup> basis), 20 mg/kg in rats (2 times the MRHD of phentermine and topiramate extended-release capsules based on estimated AUC), and 35 mg/kg in rabbits (2 times the MRHD based on estimated AUC). When rats were administered topiramate from GD 15 through lactation day 20, reductions in pre- and/or post-weaning weights occurred at dosages â¥ 2 mg/kg (2 times the MRHD of phentermine and topiramate extended-release capsules based on estimated AUC).</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">
                     <id root="f810344b-7806-47cc-9c8c-8e8ecee12b61"/>
                     <code code="77290-5" codeSystem="2.16.840.1.113883.6.1" displayName="LACTATION SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                        </paragraph>
                        <paragraph>Topiramate and phentermine are present in human milk. There are no data on the effects of topiramate and phentermine on milk production. Diarrhea and somnolence have been reported in breastfed infants with maternal use of topiramate. There are no data on the effects of phentermine in breastfed infants. Because of the potential for serious adverse reactions, including changes in sleep, irritability, hypertension, vomiting, tremor, and weight loss in breastfed infants with maternal use of phentermine, advise patients that breastfeeding is not recommended during phentermine and topiramate extended-release capsule therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_c8d68c91-d39c-4861-a99b-63f774483a8d">
                     <id root="46754fa3-2399-4922-a58c-4c996eae7edf"/>
                     <code code="77291-3" codeSystem="2.16.840.1.113883.6.1" displayName="FEMALES &amp; MALES OF REPRODUCTIVE POTENTIAL SECTION"/>
                     <title>8.3 Females and Males of
Reproductive Potential</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Pregnancy Testing</content>
                        </paragraph>
                        <paragraph>Pregnancy testing is recommended in patients who can become pregnant before initiating phentermine and topiramate extended-release capsules and monthly during phentermine and topiramate extended-release capsule therapy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Contraception</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Females</content>
                        </paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules can cause fetal harm when administered to a pregnant patient <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_9db656bc-75ac-43c9-a8ea-adf611a00791">8.1</linkHtml>)]</content>. Advise patients who can become pregnant to use effective contraception during therapy with phentermine and topiramate extended-release capsules.</paragraph>
                        <paragraph>For patients taking combined oral contraceptives (COCs), use of phentermine and topiramate extended-release capsules may cause irregular bleeding <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>. Advise patients not to discontinue taking their COC and to contact their health care provider.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_171b24a7-4705-4986-92cb-c6072bd3b89f">
                     <id root="cea45d81-061a-42cb-b9ec-4cf1e876bc37"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>Increases in linear growth were attenuated in phentermine and topiramate extended-release capsule- versus placebo-treated patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_f2ebdc9e-3271-4617-ab8c-f802d4b91688">5.6</linkHtml>)]</content>. Serious adverse reactions seen in pediatric patients using topiramate include acute angle glaucoma, oligohidrosis and hyperthermia, metabolic acidosis, cognitive and neuropsychiatric reactions, hyperammonemia and encephalopathy, and kidney stones.</paragraph>
                        <paragraph>The safety and effectiveness of phentermine and topiramate extended-release capsules in pediatric patients below the age of 12 years have not been established.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_93b6f5d9-dad4-4309-9138-f44bb2e56ec0">
                     <id root="97eacd7c-821a-41d0-9c30-98d0072a9b81"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>In the phentermine and topiramate extended-release capsules clinical trials, a total of 254 (7%) of the patients were 65 to 69 years of age; no patients 70 years of age or older were enrolled.</paragraph>
                        <paragraph>Clinical studies of phentermine and topiramate extended-release capsules did not include sufficient numbers of patients aged 65 and over to determine whether they respond differently from younger patients. In general, dose selection for an elderly patient should be cautious, usually starting at the low end of the dosing range, reflecting the greater frequency of decreased hepatic, renal, or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_3cfe6707-f747-4c13-b703-c9392903a32a">
                     <id root="a01465b7-f88a-4dc2-ba6d-58aa73aee30d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.6 Renal Impairment</title>
                     <text>
                        <paragraph>Compared to healthy volunteers with normal renal function, patients with moderate and severe renal impairment as estimated by the Cockcroft-Gault equation had higher exposures to phentermine and topiramate.</paragraph>
                        <paragraph>The recommended dosage of phentermine and topiramate extended-release capsules in patients with mild renal impairment (CrCl greater or equal to 50 and less than 80 mL/min) is the same as the recommended dosage for patients with normal renal function.</paragraph>
                        <paragraph>In patients with moderate (CrCl greater than or equal to 30 to less than 50 mL/min) and severe (CrCl less than 30 mL/min) renal impairment, the maximum recommended dosage is phentermine and topiramate extended-release capsules 7.5 mg/46 mg once daily.</paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules have not been studied in patients with end-stage renal disease on dialysis. Avoid phentermine and topiramate extended-release capsules in this patient population <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_364260b5-aa45-4a0a-a2a2-699a569736cd">2.4</linkHtml>) and Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4e00135e-f7b2-4351-834b-072e74f0f5a6">
                     <id root="18ccce8e-0c34-4cf4-a172-dcff3ced4ed7"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>8.7 Hepatic Impairment</title>
                     <text>
                        <paragraph>In patients with mild (Child-Pugh 5 to 6) and moderate (Child-Pugh 7 to 9) hepatic impairment, exposure to phentermine was higher compared to healthy volunteers with normal hepatic function. Exposure to topiramate was similar among patients with mild and moderate hepatic impairment and healthy volunteers.</paragraph>
                        <paragraph>The recommended dosage of phentermine and topiramate extended-release capsules in patients with mild hepatic impairment (Child-Pugh 5 to 6) is the same as the recommended dosage in patients with normal hepatic function.</paragraph>
                        <paragraph>In patients with moderate hepatic impairment, the maximum recommended dosage is phentermine and topiramate extended-release capsules 7.5 mg/46 mg once daily.</paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules have not been studied in patients with severe hepatic impairment (Child-Pugh score 10 to 15). Avoid phentermine and topiramate extended-release capsules in this patient population <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_e02e7bff-ca62-45b3-b30f-b285776673af">2.5</linkHtml>) and Clinical Pharmacology (<linkHtml href="#www.splportal.comLINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">12.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_2b8c2883-7aa3-421a-9448-1c535ccbf9e8">
               <id root="98ce2fee-7f07-4ea8-b98d-0ae881499425"/>
               <code code="42227-9" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG ABUSE AND DEPENDENCE SECTION"/>
               <title>9 DRUG ABUSE AND DEPENDENCE</title>
               <effectiveTime value="20241212"/>
               <component>
                  <section ID="LINK_f1f91542-053c-468a-a5a2-c0bae7c05b66">
                     <id root="06b1bf58-763b-496d-9da3-2e2cf2529118"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.1 Controlled Substance</title>
                     <text>
                        <paragraph>Phentermine and topiramate extended-release capsules contain phentermine, a Schedule IV controlled substance, and topiramate, which is not a controlled substance.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_eaed6a20-0618-41e0-b88f-6e476101a722">
                     <id root="3fc4cc79-2998-429f-bdca-a0d2a32d4bd9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.2 Abuse</title>
                     <text>
                        <paragraph>Phentermine has a known potential for abuse. Abuse is the intentional, non-therapeutic use of a drug, even once, for its desirable psychological or physiological effects.</paragraph>
                        <paragraph>Phentermine is related chemically and pharmacologically to amphetamines. Amphetamines and other stimulant drugs have been extensively abused. Abuse of amphetamines and related drugs (e.g., phentermine) may be associated with impaired control over drug use and severe social dysfunction. There are reports of patients who have increased the dosage of these drugs to many times higher than recommended. Assess the risk of abuse prior to prescribing phentermine and topiramate extended-release capsules as part of a weight reduction andÂ long-term maintenance of body weightÂ program.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_4a86212c-5ad9-48f1-8eae-da4a3b6fdb7e">
                     <id root="72692a34-0494-4904-9322-37d14365abbb"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="SPL UNCLASSIFIED SECTION"/>
                     <title>9.3 Dependence</title>
                     <text>
                        <paragraph>Physical dependence may occur in patients treated with phentermine and topiramate extended-release capsules. Physical dependence is a state that develops as a result of physiological adaptation in response to repeated drug use, manifested by withdrawal signs and symptoms after abrupt discontinuation or a significant dose reduction of a drug.</paragraph>
                        <paragraph>The following adverse reactions have been associated with the abrupt discontinuation of the individual components of phentermine and topiramate extended-release capsules:</paragraph>
                        <list listType="unordered" styleCode="Disc">
                           <item>For topiramate, abrupt discontinuation has been associated with seizures in patients without a history of seizures or epilepsy <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>.</item>
                           <item>For phentermine, abrupt discontinuation following prolonged high dosage administration results in extreme fatigue and mental depression; changes are also noted on a sleep electroencephalogram.</item>
                        </list>
                        <paragraph>Thus, in situations where rapid withdrawal of phentermine and topiramate extended-release capsules is required, appropriate medical monitoring is recommended. Patients discontinuing phentermine and topiramate extended-release capsules 15 mg/92 mg should be gradually tapered to reduce the possibility of precipitating a seizure <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">2.3</linkHtml>)]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_f6fd962b-f628-433f-86eb-f3aa2e3ed599">
               <id root="04c33b32-3125-4b98-9761-b9dc552ef75d"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>In the event of a significant overdose with phentermine and topiramate extended-release capsules, if the ingestion is recent, the stomach should be emptied immediately by gastric lavage or by induction of emesis. Appropriate supportive treatment should be provided according to the patientâs clinical signs and symptoms. In the event of an overdose of phentermine and topiramate extended-release capsules, consider contacting the Poison Help line (1-800-222-1222) or a medical toxicologist for additional overdosage management recommendations.</paragraph>
                  <paragraph>Acute overdose of phentermine may be associated with restlessness, tremor, hyperreflexia, rapid respiration, confusion, aggressiveness, hallucinations, and panic states. Fatigue and depression usually follow the central stimulation. Cardiovascular effects include arrhythmia, hypertension or hypotension, and circulatory collapse. Gastrointestinal symptoms include nausea, vomiting, diarrhea, and abdominal cramps. Fatal poisoning usually terminates in convulsions and coma. Manifestations of chronic intoxication with anorectic drugs include severe dermatoses, marked insomnia, irritability, hyperactivity, and personality changes. A severe manifestation of chronic intoxication is psychosis, often clinically indistinguishable from schizophrenia.</paragraph>
                  <paragraph>Management of acute phentermine intoxication is largely symptomatic and includes lavage and sedation with a barbiturate. Acidification of the urine increases phentermine excretion. Intravenous phentolamine has been suggested for possible acute, severe hypertension, if this complicates phentermine overdosage.</paragraph>
                  <paragraph>Topiramate overdose has resulted in severe metabolic acidosis. Other signs and symptoms include convulsions, drowsiness, speech disturbance, blurred vision, diplopia, impaired mentation, lethargy, abnormal coordination, stupor, hypotension, abdominal pain, agitation, dizziness, and depression. The clinical consequences were not severe in most cases, but deaths have been reported after overdoses involving topiramate. A patient who ingested a dose between 96 and 110 gm topiramate was admitted to hospital with coma lasting 20 to 24 hours followed by full recovery after 3 to 4 days.</paragraph>
                  <paragraph>Hemodialysis is an effective means of removing topiramate from the body.</paragraph>
               </text>
               <effectiveTime value="20241212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_83adff9a-52a3-419f-8aed-73ac0c008fd4">
               <id root="5f6032d9-4628-4ecd-a611-90968a2581bb"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Phentermine and topiramate extended-release capsules are comprised of immediate-release phentermine hydrochloride (expressed as the weight of the free base) and extended-release topiramate. Phentermine and topiramate extended-release capsules contain phentermine hydrochloride USP, a sympathomimetic amine anorectic, and topiramate USP, a sulfamate-substituted monosaccharide.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Phentermine Hydrochloride, USP</content>
                  </paragraph>
                  <paragraph>The chemical name of phentermine hydrochloride, USP is Î±,Î±-dimethylphenethylamine hydrochloride. The molecular formula is C<sub>10</sub>H<sub>15</sub>N â¢ HCl and its molecular weight is 185.7 (hydrochloride salt) or 149.2 (free base). Phentermine hydrochloride, USP is a white, odorless, hygroscopic, crystalline powder that is soluble in water, methanol, and ethanol. Its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM1"/>
                  <paragraph>
                     <content styleCode="underline">Topiramate, USP</content>
                  </paragraph>
                  <paragraph>Topiramate, USP is 2,3:4,5-di-O-isopropylidene-Î²-D-fructopyranose sulfamate. The molecular formula is C<sub>12</sub>H<sub>21</sub>NO<sub>8</sub>S and its molecular weight is 339.4. Topiramate, USP is a white to off-white crystalline powder with a bitter taste. It is freely soluble in methanol and acetone, sparingly soluble in pH 9 to pH 12 aqueous solutions and slightly soluble in pH 1 to pH 8 aqueous solutions. Its structural formula is:</paragraph>
                  <renderMultiMedia referencedObject="MM2"/>
                  <paragraph>Phentermine and topiramate extended-release capsules are for oral administration and available in four dosage strengths:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>3.75 mg/23 mg (phentermine 3.75 mg and topiramate 23 mg extended-release) (equivalent to 4.67 mg of phentermine hydrochloride, USP).</item>
                     <item>7.5 mg/46 mg (phentermine 7.5 mg and topiramate 46 mg extended-release) (equivalent to 9.33 mg of phentermine hydrochloride, USP).</item>
                     <item>11.25 mg/69 mg (phentermine 11.25 mg and topiramate 69 mg extended-release) (equivalent to 14.0 mg of phentermine hydrochloride, USP).</item>
                     <item>15 mg/92 mg (phentermine 15 mg and topiramate 92 mg extended-release) (equivalent to 18.66 mg of phentermine hydrochloride, USP).</item>
                  </list>
                  <paragraph>Each capsule contains the following inactive ingredients: colloidal silicon dioxide, copovidone, ethylcellulose, gelatin, hypromellose, microcrystalline cellulose, polysorbate 80, povidone K-30, sugar spheres (which contain sucrose and corn starch), talc, and titanium dioxide. The 3.75 mg/23 mg strength also contains iron oxide red and iron oxide yellow. The 7.5 mg/46 mg strength also contains FD&amp;C Blue #2 and iron oxide yellow. The 11.25 mg/69 mg strength also contains iron oxide yellow. The 15 mg/92 mg strength also contains iron oxide red. The imprinting ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac glaze.</paragraph>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM2">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-2.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b47070b3-fd47-42ba-a89c-8eb73f10beba">
               <id root="2733bd96-582e-4191-a438-b33e1cd6e5a2"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241212"/>
               <component>
                  <section ID="LINK_123199df-feb1-4f49-9546-3affcc838e51">
                     <id root="c315af06-bf6c-4483-bf32-a23f5ee4bcdc"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>Phentermine is a sympathomimetic amine with pharmacologic activity similar to the prototype drugs of this class used in obesity, amphetamine (d- and d/l-amphetamine). Drugs of this class used in obesity are commonly known as âanorecticsâ or âanorexigenicsâ. The effect of phentermine on weight reduction and long-term maintenance of bodyÂ weightÂ is likely mediated by release of catecholamines in the hypothalamus, resulting in reduced appetite and decreased food consumption, but other metabolic effects may also be involved. The exact mechanism of action is not known.</paragraph>
                        <paragraph>The precise mechanism of action of topiramate on weight reduction and long-term maintenance of bodyÂ weightÂ is not known. Topiramateâs effect on weight reduction and long-term maintenance of bodyÂ weightÂ may be due to its effects on both appetite suppression and satiety enhancement, induced by a combination of pharmacologic effects including augmenting the activity of the neurotransmitter gamma-aminobutyrate, modulation of voltage-gated ion channels, inhibition of AOBMPA/kainite excitatory glutamate receptors, or inhibition of carbonic anhydrase.</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_6bed2f55-21d1-4f92-8d05-cea5c21add2b">
                     <id root="2fb60eea-4ef6-4fc3-bb02-a89d0c49961f"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>Typical actions of amphetamines include central nervous system stimulation and elevation of blood pressure. Tachyphylaxis and tolerance have been demonstrated with drugs in this class.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Cardiac Electrophysiology</content>
                        </paragraph>
                        <paragraph>The effect of phentermine and topiramate extended-release capsules on the QTc interval was evaluated in a randomized, double-blind, placebo- and active-controlled (400 mg moxifloxacin), and parallel group/crossover thorough QT/QTc study. A total of 54 healthy subjects were administered phentermine and topiramate extended-release capsules 7.5 mg/46 mg at steady state and then titrated to phentermine and topiramate extended-release capsules 22.5 mg/138 mg at steady state. Phentermine and topiramate extended-release capsules 22.5 mg/138 mg [a supra-therapeutic dose resulting in a phentermine and topiramate maximum concentration (C<sub>max</sub>) of 4- and 3-times higher than those at phentermine and topiramate extended-release capsules 7.5 mg/46 mg, respectively] did not affect cardiac repolarization as measured by the change from baseline in QTc.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Glomerular Filtration Rate (GFR)</content>
                        </paragraph>
                        <paragraph>Healthy obese males and females received phentermine and topiramate extended-release capsules daily for 4 weeks (3.75 mg/23 mg on Days 1 to 3, 7.5 mg/46 mg on Days 4 to 6, 11.25 mg/69 mg on Days 7 to 9, and 15 mg/92 mg on Days 10 to 28). The glomerular filtration rate (GFR) of these participants was assessed via iohexol clearance. On average, GFR decreased during phentermine and topiramate extended-release capsule-treatment and returned to baseline within 4 weeks after discontinuing phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_b180e995-2372-4766-8c58-f170b8da4e8b">5.8</linkHtml>)]</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
               <component>
                  <section ID="LINK_2918cb2b-1703-46cc-9d3e-43426ca8d455">
                     <id root="4fe7a8d7-7e62-4c91-86f0-1f077a6d783f"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Phentermine</content>
                        </paragraph>
                        <paragraph>Upon oral administration of a single phentermine and topiramate extended-release capsule 15 mg/92 mg, the resulting mean plasma phentermine maximum concentration (C<sub>max</sub>), time to C<sub>max</sub> (T<sub>max</sub>), area under the concentration curve from time zero to the last time with measurable concentration (AUC<sub>0-t</sub>), and area under the concentration curve from time zero to infinity (AUC<sub>0-</sub>
                           <sub>â</sub>) are 49.1 ng/mL, 6 hr, 1,990 ngâ¢hr/mL, and 2,000 ngâ¢hr/mL, respectively. A high fat meal does not affect phentermine pharmacokinetics for phentermine and topiramate extended-release capsules 15 mg/92 mg. Phentermine pharmacokinetics are approximately dose-proportional from phentermine and topiramate extended-release capsules 3.75 mg/23 mg to phentermine 15 mg/topiramate 100 mg. Upon dosing phentermine 15 mg/topiramate 100 mg fixed dose combination capsule to steady state, the mean phentermine accumulation ratios for AUC and C<sub>max</sub> are both approximately 2.5.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Topiramate</content>
                        </paragraph>
                        <paragraph>Upon oral administration of a single phentermine and topiramate extended-release capsule 15 mg/92 mg, the resulting mean plasma topiramate C<sub>max</sub>, T<sub>max</sub>, AUC<sub>0-t</sub>, and AUC<sub>0-</sub>
                           <sub>â</sub>, are 1,020 ng/mL, 9 hr, 61,600 ngâ¢hr/mL, and 68,000 ngâ¢hr/mL, respectively. A high fat meal does not affect topiramate pharmacokinetics for phentermine and topiramate extended-release capsules 15 mg/92 mg. Topiramate pharmacokinetics are approximately dose-proportional from phentermine and topiramate extended-release capsules 3.75 mg/23 mg to phentermine 15 mg/topiramate 100 mg.</paragraph>
                        <paragraph>Upon dosing phentermine 15 mg/topiramate 100 mg fixed dose combination capsule to steady state, the mean topiramate accumulation ratios for AUC and C<sub>max</sub> are both approximately 4.0.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Phentermine</content>
                        </paragraph>
                        <paragraph>Phentermine is 17.5% plasma protein bound. The estimated phentermine apparent volume of distribution (Vd/F) is 348 L via population pharmacokinetic analysis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Topiramate</content>
                        </paragraph>
                        <paragraph>Topiramate is 15 to 41% plasma protein bound over the blood concentration range of 0.5 to 250 mcg/mL. The fraction bound decreased as blood topiramate increased. The estimated topiramate Vc/F (volume of the central compartment), and Vp/F (volume of the peripheral compartment) are 50.8 L, and 13.1 L, respectively, via population pharmacokinetic analysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Elimination</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Metabolism and Excretion </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Phentermine</content>
                        </paragraph>
                        <paragraph>Phentermine has two metabolic pathways, namely p-hydroxylation on the aromatic ring and N-oxidation on the aliphatic side chain. Cytochrome P450 (CYP) 3A4 primarily metabolizes phentermine but does not show extensive metabolism. Monoamine oxidase (MAO)-A and MAO-B do not metabolize phentermine. Seventy to 80% of a dose exists as unchanged phentermine in urine when administered alone. The mean phentermine terminal half-life is about 20 hours. The estimated phentermine oral clearance (CL/F) is 8.79 L/h via population pharmacokinetic analysis.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Topiramate</content>
                        </paragraph>
                        <paragraph>Topiramate does not show extensive metabolism. Six topiramate metabolites (via hydroxylation, hydrolysis, and glucuronidation) exist, none of which constitutes more than 5% of an administered dose. About 70% of a dose exists as unchanged topiramate in urine when administered alone. The mean topiramate terminal half-life is about 65 hours. The estimated topiramate CL/F is 1.17 L/h via population pharmacokinetic analysis.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Specific Populations</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Renal Impairment</content>
                        </paragraph>
                        <paragraph>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of phentermine and topiramate extended-release capsules 15 mg/92 mg in adult patients with varying degrees of chronic renal impairment compared to healthy volunteers with normal renal function. The study included patients with renal impairment classified on the basis of creatinine clearance as mild (greater or equal to 50 and less than 80 mL/min), moderate (greater than or equal to 30 and less than 50 mL/min), and severe (less than 30 mL/min). Creatinine clearance was estimated from serum creatinine based on the Cockcroft-Gault equation.</paragraph>
                        <paragraph>Compared to healthy volunteers, phentermine AUC<sub>0-inf</sub> was 91%, 45%, and 22% higher in patients with severe, moderate, and mild renal impairment, respectively; phentermine C<sub>max</sub> was 2% to 15% higher. Compared to healthy volunteers, topiramate AUC<sub>0-inf</sub> was 126%, 85%, and 25% higher for patients with severe, moderate, and mild renal impairment, respectively; topiramate C<sub>max</sub> was 6% to 17% higher. An inverse relationship between phentermine or topiramate C<sub>max</sub> or AUC and creatinine clearance was observed.</paragraph>
                        <paragraph>Phentermine and topiramate extended-release capsules have not been studied in patients with end-stage renal disease on dialysis <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_364260b5-aa45-4a0a-a2a2-699a569736cd">2.4</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_3cfe6707-f747-4c13-b703-c9392903a32a">8.6</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Patients with Hepatic Impairment</content>
                        </paragraph>
                        <paragraph>A single-dose, open-label study was conducted to evaluate the pharmacokinetics of phentermine and topiramate extended-release capsules 15 mg/92 mg in healthy volunteers with normal hepatic function compared with patients with mild (Child-Pugh score 5 to 6) and moderate (Child-Pugh score 7 to 9) hepatic impairment. In patients with mild and moderate hepatic impairment, phentermine AUC was 37% and 60% higher compared to healthy volunteers. Pharmacokinetics of topiramate was not affected in patients with mild and moderate hepatic impairment when compared with healthy volunteers. Phentermine and topiramate extended-release capsules have not been studied in patients with severe hepatic impairment (Child-Pugh score 10 to 15) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_e02e7bff-ca62-45b3-b30f-b285776673af">2.5</linkHtml>) and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_4e00135e-f7b2-4351-834b-072e74f0f5a6">8.7</linkHtml>)]</content>. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Drug Interaction Studies</content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In Vitro Assessment of Drug Interactions </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Phentermine</content>
                        </paragraph>
                        <paragraph>Phentermine is not an inhibitor of CYP isozymes CYP1A2, CYP2C9, CYP2C19, CYP2D6, CYP2E1, and CYP3A4, and is not an inhibitor of monoamine oxidases. Phentermine is not an inducer of CYP1A2, CYP2B6, and CYP3A4. Phentermine is not a P-glycoprotein substrate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Topiramate</content>
                        </paragraph>
                        <paragraph>Topiramate is not an inhibitor of CYP isozymes CYP1A2, CYP2A6, CYP2B6, CYP2C9, CYP2D6, CYP2E1, and CYP3A4/5. However, topiramate is a mild inhibitor of CYP2C19. Topiramate is a mild inducer of CYP3A4. Topiramate is not a P-glycoprotein substrate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Effects of Phentermine/Topiramate on Other Drugs</content>
                        </paragraph>
                        <paragraph>Table 7 describes the effect of phentermine/topiramate on the pharmacokinetics of coadministered drugs.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 7. Effect of Phentermine/Topiramate on the Pharmacokinetics of Coadministered Drugs</caption>
                           <col width="190.25pt"/>
                           <col width="346.1pt"/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine/Topiramate</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Coadministered Drug and Dosing Regimen</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Drug and Dose (mg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Change in AUC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Change in<br/>
                                       </content>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>*15 mg/92 mg dose QD for 16 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Metformin 500 mg BID for 5 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 23%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 16%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>*15 mg/92 mg dose QD for 21 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Sitagliptin 100 mg QD for 5 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 3%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 9%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>**15 mg/92 mg dose QD for 15 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Oral contraceptive single dose norethindrone 1 mg</paragraph>
                                    <paragraph>ethinyl estradiol 35 mcg</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 16%</paragraph>
                                    <paragraph>â 16%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 22%</paragraph>
                                    <paragraph>â 8%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule">
                                    <paragraph>*A single study examined the effect of multiple-dose phentermine and topiramate extended-release capsules 15 mg/92 mg once daily on the pharmacokinetics of multiple-dose 500 mg metformin twice daily and multiple-dose 100 mg sitagliptin once daily in 10 males and 10 females (mean BMI of 27.1 kg/m<sup>2</sup> and range of 22.2 to 32.7 kg/m<sup>2</sup>). The study participants received metformin, sitagliptin, phentermine/topiramate only, phentermine/topiramate plus probenecid, phentermine/topiramate plus metformin, and phentermine/topiramate plus sitagliptin on Days 1 to 5, 6 to 10, 11 to 28, 29, 30 to 34, and 35 to 39, respectively. The significance of these interactions is unknown.</paragraph>
                                    <paragraph>**<content styleCode="italics">See Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)</content>
                                    </paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Effect of Other Drugs on Phentermine/Topiramate</content>
                        </paragraph>
                        <paragraph>Table 8 describes the effect of other drugs on the pharmacokinetics of phentermine/topiramate.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 8. Effect of Coadministered Drugs on the Pharmacokinetics of Phentermine/Topiramate</caption>
                           <col width="178.35pt"/>
                           <col width="351.45pt"/>
                           <col/>
                           <col/>
                           <tbody>
                              <tr>
                                 <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Coadministered Drug and Dosing Regimen</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Phentermine/Topiramate</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Dose (mg)</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Change in AUC</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Change in<br/>
                                       </content>
                                       <content styleCode="bold">C<sub>max</sub>
                                       </content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Topiramate 92 mg single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15 mg phentermine single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 42%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 13%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Phentermine 15 mg single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>92 mg topiramate single dose</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 6%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>*Metformin 500 mg BID for 5 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15 mg/92 mg dose QD for 16 days</paragraph>
                                    <paragraph>phentermine topiramate</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 5%</paragraph>
                                    <paragraph>â 5%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 7%</paragraph>
                                    <paragraph>â 4%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>*Sitagliptin 100 mg QD for 5 days</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15 mg/92 mg dose QD for 21 days phentermine topiramate</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 9%</paragraph>
                                    <paragraph>â 2%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 10%</paragraph>
                                    <paragraph>â 2%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>*Probenecid 2 g QD</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>15 mg/92 mg dose QD for 11 days phentermine topiramate</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 0.3%</paragraph>
                                    <paragraph>â 0.7%</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>â 4%</paragraph>
                                    <paragraph>â 3%</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="4" styleCode=" Toprule">
                                    <paragraph>*The same single study examined the effect of multiple-dose 500 mg metformin twice daily, a single-dose 2 g probenecid, and multiple-dose 100 mg sitagliptin once daily on the pharmacokinetics of multiple-dose phentermine/topiramate 15 mg/92 mg once daily in 10 males and 10 females (mean BMI of 27.1 kg/m<sup>2</sup> and range of 22.2 to 32.7 kg/m<sup>2</sup>). The study participants received metformin, sitagliptin, phentermine/topiramate only, phentermine/topiramate plus probenecid, phentermine/topiramate plus metformin, and phentermine/topiramate plus sitagliptin on Days 1 to 5, 6 to 10, 11 to 28, 29, 30 to 34, and 35 to 39, respectively.</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Effects of Topiramate Alone on Other Drugs and Effects of Other Drugs on Topiramate </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">Antiepileptic Drugs</content>
                        </paragraph>
                        <paragraph>Potential interactions between topiramate and standard antiepileptic (AED) drugs were assessed in controlled clinical pharmacokinetic studies in patients with epilepsy. The effects of these interactions on mean plasma AUCs are summarized in Table 9.</paragraph>
                        <paragraph>In Table 9, the second column (AED concentration) describes what happens to the concentration of the AED listed in the first column when topiramate is added. The third column (topiramate concentration) describes how the coadministration of a drug listed in the first column modifies the concentration of topiramate in experimental settings when topiramate was given alone <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <table width="800px" cellspacing="0" cellpadding="5">
                           <caption>Table 9. Summary of AED Interactions with Topiramate</caption>
                           <col width="159.1pt"/>
                           <col width="205.45pt"/>
                           <col width="169pt"/>
                           <tbody>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">AED<br/>
                                       </content>
                                       <content styleCode="bold">Coadministered</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">AED<br/>
                                       </content>
                                       <content styleCode="bold">Concentration</content>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>
                                       <content styleCode="bold">Topiramate<br/>
                                       </content>
                                       <content styleCode="bold">Concentration</content>
                                    </paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Phenytoin</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC or 25% increase<sup>a</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>48% decrease</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Carbamazepine (CBZ)</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>40% decrease</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>CBZ epoxide<sup>b</sup>
                                    </paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NE</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Valproic acid</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>11% decrease</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>14% decrease</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Phenobarbital</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NE</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Primidone</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NE</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>Lamotrigine</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>NC at TPM doses up to 400 mg/day</paragraph>
                                 </td>
                                 <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                                    <paragraph>13% decrease</paragraph>
                                 </td>
                              </tr>
                              <tr>
                                 <td colspan="3" styleCode=" Toprule">
                                    <paragraph>
                                       <sup>a</sup> Plasma concentration increased 25% in some patients, generally those on a twice a day dosing regimen of phenytoin.<br/>
                                       <sup>b</sup> Is not administered but is an active metabolite of carbamazepine.<br/>
            NC = Less than 10% change in plasma concentration; NE = Not Evaluated; TPM = topiramate</paragraph>
                                 </td>
                              </tr>
                           </tbody>
                        </table>
                        <paragraph>
                           <content styleCode="italics">Digoxin</content>
                        </paragraph>
                        <paragraph>In a single-dose study, serum digoxin AUC was decreased by 12% with concomitant topiramate administration. The clinical relevance of this observation has not been established.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Hydrochlorothiazide</content>
                        </paragraph>
                        <paragraph>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of hydrochlorothiazide (HCTZ) (25 mg q24h) and topiramate (96 mg q12h) when administered alone and concomitantly. The results of this study indicate that topiramate C<sub>max</sub> increased by 27% and AUC increased by 29% when HCTZ was added to topiramate. The clinical significance of this change is unknown. The steady-state pharmacokinetics of HCTZ were not significantly influenced by the concomitant administration of topiramate. Clinical laboratory results indicated decreases in serum potassium after topiramate or HCTZ administration, which were greater when HCTZ and topiramate were administered in combination <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>) and Warnings and Precautions (<linkHtml href="#LINK_7850101b-a9e8-41ed-b234-615c1f24fc79">5.12</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pioglitazone</content>
                        </paragraph>
                        <paragraph>A drug-drug interaction study conducted in healthy volunteers evaluated the steady-state pharmacokinetics of topiramate (96 mg twice daily) and pioglitazone (30 mg daily) when administered alone and concomitantly for 7 days. A 15% decrease in the area under the concentration-time curve during a dosage interval at steady state (AUC<sub>Ï,ss</sub>) of pioglitazone with no alteration in maximum steady-state plasma drug concentration during a dosage interval (C<sub>max,ss</sub>) was observed. This finding was not statistically significant. In addition, a 13% and 16% decrease in C<sub>max,ss</sub> and AUC<sub>Ï,ss</sub> respectively, of the active hydroxy-metabolite was noted as well as a 60% decrease in C<sub>max,ss</sub> and AUC<sub>Ï,ss</sub> of the active keto-metabolite <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Glyburide</content>
                        </paragraph>
                        <paragraph>A drug-drug interaction study conducted in patients with type 2 diabetes mellitus evaluated the steady-state pharmacokinetics of glyburide (5 mg/day) alone and concomitantly with topiramate (150 mg/day). There was a 22% decrease in C<sub>max</sub> and a 25% reduction in AUC<sub>24</sub> for glyburide during topiramate administration. Systemic exposure (AUC) of the active metabolites, 4-<content styleCode="italics">trans</content>-hydroxyglyburide (M1), and 3-<content styleCode="italics">cis</content>-hydroxyglyburide (M2), was reduced by 13% and 15%, and C<sub>max</sub> was reduced by 18% and 25%, respectively. The steady-state pharmacokinetics of topiramate were unaffected by concomitant administration of glyburide.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Lithium</content>
                        </paragraph>
                        <paragraph>In patients, the pharmacokinetics of lithium were unaffected during treatment with topiramate at doses of 200 mg/day; however, there was an observed increase in systemic exposure of lithium (27% for C<sub>max</sub> and 26% for AUC) following topiramate doses up to 600 mg/day.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Haloperidol</content>
                        </paragraph>
                        <paragraph>The pharmacokinetics of a single dose of haloperidol (5 mg) were not affected following multiple dosing of topiramate (100 mg every 12 hours) in 13 healthy adults (6 males, 7 females).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Amitriptyline</content>
                        </paragraph>
                        <paragraph>There was a 12% increase in AUC and C<sub>max</sub> for amitriptyline (25 mg per day) in 18 normal subjects (9 males, 9 females) receiving 200 mg/day of topiramate <content styleCode="italics">[see Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>)]</content>.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Sumatriptan</content>
                        </paragraph>
                        <paragraph>Multiple dosing of topiramate (100 mg every 12 hrs) in 24 healthy volunteers (14 males, 10 females) did not affect the pharmacokinetics of single-dose sumatriptan either orally (100 mg) or subcutaneously (6 mg).</paragraph>
                        <paragraph>
                           <content styleCode="italics">Risperidone</content>
                        </paragraph>
                        <paragraph>When administered concomitantly with topiramate at escalating doses of 100, 250, and 400 mg/day, there was a reduction in risperidone systemic exposure (16% and 33% for steady-state AUC at the 250 and 400 mg/day doses of topiramate). No alterations of 9-hydroxyrisperidone levels were observed. Coadministration of topiramate 400 mg/day with risperidone resulted in a 14% increase in C<sub>max</sub> and a 12% increase in AUC<sub>12</sub> of topiramate. There were no clinically significant changes in the systemic exposure of risperidone plus 9-hydroxyrisperidone or of topiramate; therefore, this interaction is not likely to be of clinical significance.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Propranolol</content>
                        </paragraph>
                        <paragraph>Multiple dosing of topiramate (200 mg/day) in 34 healthy volunteers (17 males, 17 females) did not affect the pharmacokinetics of propranolol following daily 160 mg doses. Propranolol doses of 160 mg/day in 39 volunteers (27 males, 12 females) had no effect on the exposure to topiramate, at a dose of 200 mg/day of topiramate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Dihydroergotamine</content>
                        </paragraph>
                        <paragraph>Multiple dosing of topiramate (200 mg/day) in 24 healthy volunteers (12 males, 12 females) did not affect the pharmacokinetics of a 1 mg subcutaneous dose of dihydroergotamine. Similarly, a 1 mg subcutaneous dose of dihydroergotamine did not affect the pharmacokinetics of a 200 mg/day dose of topiramate in the same study.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Diltiazem</content>
                        </paragraph>
                        <paragraph>Coadministration of diltiazem hydrochloride extended-release with topiramate (150 mg/day) resulted in a 10% decrease in C<sub>max</sub> and a 25% decrease in diltiazem AUC, a 27% decrease in C<sub>max</sub> and an 18% decrease in des-acetyl diltiazem AUC, and no effect on N-desmethyl diltiazem. Coadministration of topiramate with diltiazem hydrochloride extended-release resulted in a 16% increase in C<sub>max</sub> and a 19% increase in AUC<sub>12</sub> of topiramate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Venlafaxine</content>
                        </paragraph>
                        <paragraph>Multiple dosing of topiramate (150 mg/day) in healthy volunteers did not affect the pharmacokinetics of venlafaxine or O-desmethyl venlafaxine. Multiple dosing of venlafaxine (150 mg extended release) did not affect the pharmacokinetics of topiramate.</paragraph>
                        <paragraph>
                           <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_24ca90b2-6335-4021-b922-370a464aff0f">
               <id root="b83c673a-3280-47ef-843f-e23059dc7bdf"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241212"/>
               <component>
                  <section ID="LINK_7dfb4b13-fed6-4f25-bc49-5068301c5035">
                     <id root="11314d43-072e-4a40-91ab-4a5735e70716"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Phentermine/Topiramate</content>
                        </paragraph>
                        <paragraph>No animal studies have been conducted with the combination of phentermine/topiramate to evaluate carcinogenesis, mutagenesis, or impairment of fertility. The following data are based on findings in studies performed individually with phentermine or topiramate, phentermine and topiramate extended-release capsuleâs two active ingredients.</paragraph>
                        <paragraph>
                           <content styleCode="underline">Phentermine</content>
                        </paragraph>
                        <paragraph>Phentermine was not mutagenic or clastogenic with or without metabolic activation in the Ames bacterial mutagenicity assay, a chromosomal aberration test in Chinese hamster lung (CHL-K1) cells, or an <content styleCode="italics">in vivo</content> micronucleus assay.</paragraph>
                        <paragraph>Rats were administered oral doses of 3, 10, and 30 mg/kg/day phentermine for 2 years. There was no evidence of carcinogenicity at the highest dose of phentermine (30 mg/kg) which is approximately 11 to 15 times the maximum recommended clinical dose of phentermine and topiramate extended-release capsules 15 mg/92 mg based on AUC exposure.</paragraph>
                        <paragraph>No animal studies have been conducted with phentermine to determine the potential for impairment of fertility. </paragraph>
                        <paragraph>
                           <content styleCode="underline">Topiramate</content>
                        </paragraph>
                        <paragraph>Topiramate did not demonstrate genotoxic potential when tested in a battery of <content styleCode="italics">in vitro</content> and <content styleCode="italics">in vivo</content> assays. Topiramate was not mutagenic in the Ames test or the <content styleCode="italics">in vitro</content> mouse lymphoma assay; it did not increase unscheduled DNA synthesis in rat hepatocytes <content styleCode="italics">in vitro</content>; and it did not increase chromosomal aberrations in human lymphocytes <content styleCode="italics">in vitro</content> or in rat bone marrow <content styleCode="italics">in vivo</content>.</paragraph>
                        <paragraph>An increase in urinary bladder tumors was observed in mice given topiramate (20, 75, and 300 mg/kg) in the diet for 21 months. The elevated bladder tumor incidence, which was statistically significant in males and females receiving 300 mg/kg, was primarily due to the increased occurrence of a smooth muscle tumor considered histomorphologically unique to mice. Plasma exposures in mice receiving 300 mg/kg were approximately 2 to 4 times steady-state exposures measured in patients receiving topiramate monotherapy at the MRHD of phentermine and topiramate extended-release capsules 15 mg/92 mg. The relevance of this finding to human carcinogenic risk is uncertain. No evidence of carcinogenicity was seen in rats following oral administration of topiramate for 2 years at doses up to 120 mg/kg (approximately 4 to 10 times the MRHD of phentermine and topiramate extended-release capsules based on AUC estimates).</paragraph>
                        <paragraph>No adverse effects on male or female fertility were observed in rats at doses up to 100 mg/kg (approximately 4 to 8 times male and female MRHD exposures of phentermine and topiramate extended-release capsules based on AUC).</paragraph>
                     </text>
                     <effectiveTime value="20241212"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_3b3b30e3-796c-4f9e-9835-f7ecffe4ccf2">
               <id root="183a14df-7295-4929-a45b-6a0bb58559e2"/>
               <code code="34092-7" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL STUDIES SECTION"/>
               <title>14 CLINICAL STUDIES</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Clinical Studies in Adults</content>
                  </paragraph>
                  <paragraph>The effect of phentermine and topiramate extended-release capsules on weight loss in conjunction with reduced caloric intake and increased physical activity was studied in two randomized, double-blind, placebo-controlled studies in patients with obesity (Study 1) and patients with obesity or overweight with two or more significant co-morbidities (Study 2). Both studies had a 4-week titration period, followed by 52 weeks of treatment. There were two co-primary efficacy outcomes measured after 1 year of treatment (Week 56): 1) the percent weight loss from baseline; and 2) treatment response defined as achieving at least 5% weight loss from baseline.</paragraph>
                  <paragraph>In Study 1, patients with obesity (BMI greater than or equal to 35 kg/m<sup>2</sup>) were randomized to receive 1 year of treatment with placebo (N=514), phentermine and topiramate extended-release capsules 3.75 mg/23 mg (N=241), or phentermine and topiramate extended-release capsules 15 mg/92 mg (N=512) in a 2:1:2 ratio. Patients ranged in age from 18-71 years old (mean age 43) and 83% were female. Approximately 80% were White, 18% were Black or African American, and 15% were Hispanic or Latino ethnicity. At the beginning of the study the average weight and BMI of patients was 116 kg and 42 kg/m<sup>2</sup>, respectively. Patients with type 2 diabetes mellitus were excluded from participating in Study 1. During the study, a well-balanced, reduced-calorie diet to result in an approximate 500 kcal/day decrease in caloric intake was recommended to all patients and patients were offered nutritional and lifestyle modification counseling.</paragraph>
                  <paragraph>In Study 2, patients with overweight or obesity were randomized to receive 1 year of treatment with placebo (N=994), phentermine and topiramate extended-release capsules 7.5 mg/46 mg (N=498), or phentermine and topiramate extended-release capsules 15 mg/92 mg (N=995) in a 2:1:2 ratio. Eligible patients had to have a BMI greater than or equal to 27 kg/m<sup>2</sup> and less than or equal to 45 kg/m<sup>2</sup> (there was no lower limit on BMI for patients with type 2 diabetes mellitus) and two or more of the following obesity-related co-morbid conditions:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>Elevated blood pressure (greater than or equal to 140/90 mmHg, or greater than or equal to 130/85 mmHg for diabetics) or requirement for greater than or equal to 2 antihypertensive medications;</item>
                     <item>Triglycerides greater than 200 to 400 mg/dL or were receiving treatment with 2 or more lipid-lowering agents;</item>
                     <item>Elevated fasting blood glucose (greater than 100 mg/dL) or diabetes; and/or</item>
                     <item>Waist circumference greater than or equal to 102 cm for men or greater than or equal to 88 cm for females.</item>
                  </list>
                  <paragraph>Patients ranged in age from 19 to 71 years of age (mean age 51) and 70% were female. Approximately 86% were White, 12% were Black or African American, and 13% were Hispanic or Latino ethnicity. The average weight and BMI of patients at the start of the study was 103 kg and 36.6 kg/m<sup>2</sup>, respectively. Approximately half (53%) of patients had hypertension at the start of the study. There were 388 (16%) patients with type 2 diabetes mellitus at the start of the study. During the study, a well-balanced, reduced-calorie diet to result in an approximate 500 kcal/day decrease in caloric intake was recommended to all patients and patients were offered nutritional and lifestyle modification counseling.</paragraph>
                  <paragraph>The percentage of randomized patients who withdrew from each study prior to week 56 was 40% in Study 1, and 31% in Study 2.</paragraph>
                  <paragraph>Table 10 provides the results for weight loss at 1 year in Studies 1 and 2. After 1 year of treatment with phentermine and topiramate extended-release capsules, all dose levels resulted in statistically significant weight loss compared to placebo (see Table 10, Figure 1 and Figure 2). A statistically significant greater proportion of the patients randomized to phentermine and topiramate extended-release capsules than placebo achieved 5% and 10% weight loss.</paragraph>
                  <table width="1000px" cellspacing="0" cellpadding="5">
                     <caption>Table 10. Weight Loss at One Year in Adult Patients in Studies 1 and 2</caption>
                     <col width="131.5pt"/>
                     <col width="208.2pt"/>
                     <col width="199.15pt"/>
                     <col/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Analysis Method</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Study 1 (Obesity)</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="3" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Study 2 (Obesity or Overweight with <br/>
            Co-morbidities)</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                 </content>
                                 <content styleCode="bold">3.75 mg/23 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                 </content>
                                 <content styleCode="bold">15 mg/92 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" valign="bottom" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Placebo</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
                                 </content>
                                 <content styleCode="bold">7.5 mg/46 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">15 mg/92 mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>ITT-LOCF (Primary)*</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 498</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 234</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 498</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 979</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 488</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>n = 981</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Weight (kg)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>115.7</paragraph>
                              <paragraph>(21.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>118.6 (21.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>115.2 (20.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>103.3</paragraph>
                              <paragraph>(18.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>102.8 (18.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>103.1 (17.6)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>% LS Mean Change from baseline (SE)**</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.6 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.1 (0.5)<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-10.9 (0.4)<sup>â â¡</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.2 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-7.8 (0.4)<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-9.8 (0.3)<sup>â â¡</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Difference from placebo <br/>
            (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>3.5 <br/>
            (2.4 to 4.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>9.4 <br/>
            (8.4 to 10.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>6.6 <br/>
            (5.8 to 7.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>8.6 <br/>
            (8.0 to 9.3)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Percentage of patients losing greater than or equal to 5% body weight</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>17%</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>45%<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>67%<sup>â â¡</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>21%</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>62%<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>70%<sup>â â¡</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Risk Difference vs. placebo (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>27.6 <br/>
            (20.4 to 34.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>49.4 <br/>
            (44.1 to 54.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>41.3 <br/>
            (36.3 to 46.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>49.2 <br/>
            (45.4 to 53.0)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Percentage of patients losing greater than or equal to 10% body weight</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>7%</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>19%<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>47%<sup>â â¡</sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>7%</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>37%<sup>â </sup>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>48%<sup>â â¡</sup>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Risk Difference vs. placebo (95% CI)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>11.4 <br/>
            (5.9 to 16.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>39.8 <br/>
            (34.8 to 44.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>29.9 <br/>
            (25.3 to 34.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>40.3 <br/>
            (36.7 to 43.8)</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="7" styleCode=" Toprule">
                              <paragraph>SD=standard deviation; LS=least-squares; SE=standard error; CI=confidence interval</paragraph>
                              <paragraph>* Uses all available data from subjects in ITT population, including data collected from subjects who discontinued drug but remained on study. Last Observation Carried Forward (LOCF) method used to impute missing data.</paragraph>
                              <paragraph>
                                 <sup>â </sup> p &lt; 0.0001 vs. placebo based on least-squares (LS) mean from an analysis of covariance.</paragraph>
                              <paragraph>
                                 <sup>â¡</sup> p &lt; 0.01 vs. 3.75 mg/23 mg (Study 1) or 7.5 mg/46 mg (Study 2) dose. Type 1 error was controlled across all pairwise treatment comparisons.</paragraph>
                              <paragraph>** Adjusted for baseline bodyweight (Study 1) and baseline bodyweight and diabetic status (Study 2).</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="900px" cellspacing="0" cellpadding="0" border="0">
                     <col width="275.4pt"/>
                     <col width="261pt"/>
                     <tbody>
                        <tr>
                           <td align="center">
                              <paragraph>
                                 <content styleCode="bold">Figure 1. Study 1 Percent Weight Change from Baseline to <br/>
            Week 56 in Adults with Obesity</content>
                              </paragraph>
                           </td>
                           <td align="center">
                              <paragraph>
                                 <content styleCode="bold">Figure 2. Study 2 Percent Weight Change from Baseline to <br/>
            Week 56 in Adults with Obesity or Overweight with Co-morbidities</content>
                              </paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <renderMultiMedia referencedObject="MM3"/>
                  <paragraph>The changes in cardiovascular, metabolic, and anthropometric risk factors associated with obesity from Study 1 and 2 are presented in Table 11 and Table 12. </paragraph>
                  <table width="1000px" cellspacing="0" cellpadding="5">
                     <caption>Table 11. Least-Squares (LS) Mean<sup>â </sup> Change from Baseline and Treatment Difference from Placebo in Cardiometabolic Parameters in Adults Following One Year of Treatment in Study 1 (Obesity)</caption>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Study 1 (Obesity)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
            Placebo<br/>
            (N=498)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            3.75 mg/23 mg<br/>
            (N=234)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            15 mg/92 mg<br/>
            (N=498)</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules â Placebo: LS Mean</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            3.75 mg/23 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            15 mg/92 mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Heart Rate, bpm</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>73.2 (8.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>72.3 (9.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>73.1 (9.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+1.1</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+1.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-0.8 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.3 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+1.0 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Systolic Blood Pressure, mmHg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>121.9 (11.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>122.5 (11.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>121.9 (11.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.8</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.9 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.8 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.9 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Diastolic Blood Pressure, mmHg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>77.2 (7.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>77.8 (7.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>77.4 (7.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-0.5</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.9</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.4 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-0.1 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.5 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Total Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>194.3 (36.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>196.3 (36.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>192.7 (33.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.9</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.5 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.4 (0.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-6.0 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">LDL-Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>120.9 (32.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>122.8 (33.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>120.0 (30.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.2</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.5 (1.0)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-7.7 (1.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-8.4 (0.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">HDL-Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>49.5 (13.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>50.0 (11.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>49.7 (11.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.5</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+3.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.0 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.5 (1.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+3.5 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Triglycerides, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>119.0 (39.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>117.5 (40.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>114.6 (37.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.9</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-14.3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+9.1 (2.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+5.2 (3.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.2 (2.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Fasting Glucose, mg/dL</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>93.1 (8.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>93.9 (9.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>93.0 (9.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.2</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.5</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+1.9 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.8 (0.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-0.6 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Waist Circumference, cm</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>120.5 (14.0)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>121.5 (15.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>120.0 (14.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.5*</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-7.8*</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.1 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.6 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-10.9 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>SD=standard deviation; SE=standard error</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>*</sup> Statistically significant versus placebo based on the pre-specified method for controlling Type I error across multiple doses</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>â </sup> Study 1 adjusted for baseline bodyweight</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <table width="1000px" cellspacing="0" cellpadding="5">
                     <caption>Table 12. Least-Squares (LS) Mean<sup>â </sup> Change from Baseline and Treatment Difference from Placebo in Cardiometabolic Parameters in Adults Following One Year of Treatment in Study 2 (Obese or Overweight with Comorbidities)</caption>
                     <col width="174.6pt"/>
                     <col width="71.4pt"/>
                     <col width="77.35pt"/>
                     <col width="77.3pt"/>
                     <col width="153.75pt"/>
                     <col/>
                     <tbody>
                        <tr>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
            Study 2 (Overweight and Obese with Comorbidities)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">
                                    <br/>
            Placebo<br/>
            (N=979)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            7.5 mg/46 mg<br/>
            (N=488)</content>
                              </paragraph>
                           </td>
                           <td align="center" rowspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules</content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">15 mg/92 mg<br/>
            (N=981)</content>
                              </paragraph>
                           </td>
                           <td align="center" colspan="2" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules â Placebo: LS Mean</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            7.5 mg/46 mg</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Phentermine and Topiramate Extended-Release Capsules<br/>
            15 mg/92 mg</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Heart Rate, bpm</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>72.1 (9.9)<br/>
            -0.3 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>72.2 (10.1)<br/>
            +0.3 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>72.6 (10.1)<br/>
            +1.4 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.6</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+1.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Systolic Blood Pressure, mmHg </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>128.9 (13.5)<br/>
            -2.4 (0.48)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>128.5 (13.6)<br/>
            -4.7 (0.63)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>127.9 (13.4)<br/>
            -5.6 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.3</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.2</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Diastolic Blood Pressure, mmHg </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>81.1 (9.2)<br/>
            -2.7 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>80.6 (8.7)<br/>
            -3.4 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>80.2 (9.1)<br/>
            -3.8 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-0.7</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.1</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Total Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>205.8 (41.7)<br/>
            -3.3 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>201.0 (37.9)<br/>
            -4.9 (0.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>205.4 (40.4)<br/>
            -6.3 (0.5)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-1.6</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.0</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">LDL-Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>124.2 (36.2)<br/>
            -4.1 (0.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>120.3 (33.7)<br/>
            -3.7 (1.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>123.9 (35.6)<br/>
            -6.9 (0.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+0.4</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.8</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">HDL-Cholesterol, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>48.9 (13.8)<br/>
            +1.2 (0.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>48.5 (12.8)<br/>
            +5.2 (0.9)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>49.1 (13.8)<br/>
            +6.8 (0.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+4.0</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>+5.6</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Triglycerides, %</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>163.5 (76.3)<br/>
            +4.7 (1.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>161.1 (72.2)<br/>
            -8.6 (2.2)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>161.9 (73.4)<br/>
            -10.6 (1.7)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-13.3</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-15.3</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Fasting Insulin, (ÂµIU/mL)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD)</paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>17.8 (13.2)<br/>
            +0.7 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>18.0 (12.9)<br/>
            -3.5 (1.1)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>18.4 (17.5)<br/>
            -4.0 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-4.2</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-4.7</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Fasting Glucose, mg/dL </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>106.6 (23.7)<br/>
            +2.3 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>106.2 (21.0)<br/>
            -0.1 (0.8)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>105.7 (21.4)<br/>
            -1.3 (0.6)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-2.4</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-3.6</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Waist Circumference, cm </content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule"/>
                        </tr>
                        <tr>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph> Baseline mean (SD) </paragraph>
                              <paragraph> LS Mean Change (SE)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>113.4 (12.2)<br/>
            -2.4 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>112.7 (12.4)<br/>
            -7.6 (0.4)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>113.2 (12.2)<br/>
            -9.2 (0.3)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-5.2<sup>*</sup>
                                 <br/>
                                 <br/>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>-6.8<sup>*</sup>
                                 <br/>
                                 <br/>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>SD=standard deviation; SE=standard error</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>*</sup> Statistically significant versus placebo based on the pre-specified method for controlling Type I error across multiple doses </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="6">
                              <paragraph>
                                 <sup>â </sup> Study 2 adjusted for baseline bodyweight and diabetic status</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Among the 388 subjects with type 2 diabetes mellitus treated in Study 2, reductions in HbA1c from baseline (6.8%) were 0.1% for placebo compared to 0.4% and 0.4% with phentermine and topiramate extended-release capsules 7.5 mg/46 mg and phentermine and topiramate extended-release capsules 15 mg/92 mg, respectively.</paragraph>
                  <paragraph>
                     <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information.</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM3">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-3.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_387b587b-343a-4327-b60a-f786616c708b">
               <id root="41fa8041-58e3-4e8e-bbe7-c87d9ee4c03b"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <text>
                  <paragraph>Phentermine and topiramate extended-release capsules are available as follows (see Table 15):</paragraph>
                  <table width="800px" cellspacing="0" cellpadding="5">
                     <caption>Table 15. Phentermine and Topiramate Extended-Release Capsules Presentations</caption>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <col width="171.9pt"/>
                     <tbody>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Strength<br/>
                                 </content>
                                 <content styleCode="bold">(phentermine mg/topiramate mg)</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Description</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How Supplied</content>
                              </paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">NDC #</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>3.75 mg/23 mg <br/>
            extended-release capsules</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>White opaque cap printed with WPI, orange opaque body printed with 2196</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Unit of Use Bottle (30 capsules)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>0480-3297-56</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>7.5 mg/46 mg <br/>
            extended-release capsules</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>White opaque cap printed with WPI, green opaque body printed with 2195</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Unit of Use Bottle (30 capsules)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>0480-3296-56</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>11.25 mg/69 mg <br/>
            extended-release capsules</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Light yellow opaque cap printed with WPI, white opaque body printed with 2299</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Unit of Use Bottle (30 capsules)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>0480-2299-56</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>15 mg/92 mg <br/>
            extended-release capsules</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>White opaque cap printed with WPI, dark scarlet opaque body printed with 2194</paragraph>
                           </td>
                           <td styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>Unit of Use Bottle (30 capsules)</paragraph>
                           </td>
                           <td align="center" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>0480-3295-56</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>Store at 20Â° to 25Â°C (68Â° to 77Â°F) [See USP Controlled Room Temperature]. Keep container tightly closed and protect from moisture. Keep out of reach of children.</paragraph>
               </text>
               <effectiveTime value="20241212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_fcf3a7bf-ecc7-4005-8ed7-c038b8ade9ef">
               <id root="41a087f3-817a-4dbc-bff8-caec5e508aac"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>Advise the patient to read the FDA-approved patient labeling (<linkHtml href="#www.splportal.comLINK_f02ebf33-641d-4f60-8e85-19fe5b2e9277">Medication Guide</linkHtml>). </paragraph>
                  <paragraph>
                     <content styleCode="underline">Embryo-Fetal Toxicity</content>
                  </paragraph>
                  <paragraph>Inform patients who can become pregnant that phentermine and topiramate extended-release capsules can cause fetal harm and patients should avoid getting pregnant while taking phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#www.splportal.comLINK_074785d7-e224-4012-b5df-bd6ac6606c97">5.1</linkHtml>), Drug Interactions (<linkHtml href="#www.splportal.comLINK_579c94f3-8ef1-49d7-b024-175fbf7bea78">7</linkHtml>), and Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_c8d68c91-d39c-4861-a99b-63f774483a8d">8.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>Advise patients who can become pregnant:</paragraph>
                  <list listType="unordered" styleCode="Disc">
                     <item>that pregnancy testing is recommended before initiating phentermine and topiramate extended-release capsules and monthly during therapy;</item>
                     <item>to use effective contraception during phentermine and topiramate extended-release capsule therapy;</item>
                     <item>who experience spotting while taking a combined oral contraceptive to notify their health care provider;</item>
                     <item>with a known or suspected pregnancy to stop phentermine and topiramate extended-release capsules immediately and notify their health care provider.</item>
                  </list>
                  <paragraph>
                     <content styleCode="underline">Access to Phentermine and Topiramate Extended-Release Capsules</content>
                  </paragraph>
                  <paragraph>Advise patients that phentermine and topiramate extended-release capsules is only available through certified pharmacies that are enrolled in the phentermine and topiramate extended-release capsules certified pharmacy network. Advise patients on how to access phentermine and topiramate extended-release capsules through certified pharmacies. Additional information may be obtained via the website www.PhenTopREMS.com or by telephone at 1-800-269-6816 or by FAX at 1-800-558-6165.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Suicidal Behavior and Ideation and Mood and Sleep Disorders</content>
                  </paragraph>
                  <paragraph>Inform patients that phentermine and topiramate extended-release capsules can increase the risk of mood changes, sleep disorders, depression, and suicidal ideation. Advise patients to tell their health care provider(s) immediately if mood changes, depression, or suicidal ideation occur <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_88e905e2-0293-48df-99bc-a7b7ae095980">5.2</linkHtml>, <linkHtml href="#LINK_d1821dbd-fec3-47f4-a506-0ba68056ea48">5.4</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Ophthalmologic Adverse Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients that phentermine and topiramate extended-release capsules can increase the risk of acute myopia, secondary angle closure glaucoma, and visual field defects. Advise patients to immediately report symptoms of severe and persistent eye pain or significant changes in their vision to their health care provider(s) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_515ed8db-32ae-468b-8622-c54a0f4b8dfa">5.3</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cognitive Impairment</content>
                  </paragraph>
                  <paragraph>Inform patients that phentermine and topiramate extended-release capsules can cause confusion, concentration, and word-finding difficulties. Inform patients that the concomitant use of alcohol or central nervous system (CNS) depressant drugs with phentermine and topiramate extended-release capsules, may increase the risk of dizziness, cognitive adverse reactions, drowsiness, light-headedness, impaired coordination and somnolence.</paragraph>
                  <paragraph>Advise patients to tell their health care provider(s) about any changes in attention, concentration, memory, difficulty finding words, or other cognitive functions.</paragraph>
                  <paragraph>Advise patients not to drive or operate machinery until they have gained sufficient experience on phentermine and topiramate extended-release capsules to gauge whether it adversely affects their mental performance, motor performance, and/or vision. Advise patients to avoid excessive alcohol intake while taking phentermine and topiramate extended-release capsules <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_9ad9259d-09a3-409b-9025-0739a026b9e1">5.5</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Slowing of Linear Growth</content>
                  </paragraph>
                  <paragraph>Discuss with the patient and caregiver that long-term phentermine and topiramate extended-release capsules treatment may attenuate growth as reflected by slower height increase in pediatric patients <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_f2ebdc9e-3271-4617-ab8c-f802d4b91688">5.6</linkHtml>)</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Metabolic Acidosis</content>
                  </paragraph>
                  <paragraph>Inform patients that phentermine and topiramate extended-release capsules can increase the risk of metabolic acidosis. Advise patients to tell their health care provider(s) about any factors that can increase the risk of acidosis (e.g. prolonged diarrhea, surgery, and high protein/low carbohydrate diet, and/or concomitant medications such as carbonic anhydrase inhibitors) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_2e4f5ed3-c858-44e2-9a7f-d4dc164e7a15">5.7</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Risk of Seizures with Abrupt Withdrawal of Phentermine and Topiramate Extended-Release Capsules</content>
                  </paragraph>
                  <paragraph>Inform patients that abrupt withdrawal of topiramate has been associated with seizures in individuals without a history of seizures or epilepsy. Advise patients not to abruptly stop phentermine and topiramate extended-release capsules without first talking to their health care provider(s) <content styleCode="italics">[see Dosage and Administration (<linkHtml href="#LINK_b1ab0bd7-0bc3-452f-88cd-65bbfe71344c">2.3</linkHtml>) and Warnings and Precautions (<linkHtml href="#LINK_616a50f2-2273-4a63-a5db-0cf7541c6a37">5.9</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Kidney Stones</content>
                  </paragraph>
                  <paragraph>Inform patients that use of phentermine and topiramate extended-release capsules has been associated with kidney stone formation. Advise patients to increase fluid intake to increase urinary output which can decrease the concentration of substances involved in kidney stone formation. Advise patients to report symptoms of severe side or back pain, and/or blood in their urine to their health care provider(s) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_5da57159-b1c5-4f5c-8e81-da62441b9205">5.10</linkHtml>) and Adverse Reactions (<linkHtml href="#www.splportal.comLINK_d4004f8a-a849-4cd8-a071-d85eaf8aa74d">6.1</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Oligohidrosis and Hyperthermia</content>
                  </paragraph>
                  <paragraph>Inform patients that oligohidrosis (decreased sweating) has been reported in association with the use of topiramate. Advise patients to monitor for decreased sweating and increased body temperature during physical activity, especially in hot weather <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_29349ff4-26fe-4ca4-86e3-17d65cda63ff">5.11</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious Skin Reactions</content>
                  </paragraph>
                  <paragraph>Inform patients that serious skin reactions have been reported with use of topiramate. Inform patients of the signs of serious skin reactions and advise patients to report signs of a skin reaction to their health care provider(s) <content styleCode="italics">[see Warnings and Precautions (<linkHtml href="#LINK_4a7235c0-3712-4670-83e8-525f3a849a72">5.13</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Lactation</content>
                  </paragraph>
                  <paragraph>Advise patients that breastfeeding is not recommended during phentermine and topiramate extended-release capsule treatment <content styleCode="italics">[see Use in Specific Populations (<linkHtml href="#www.splportal.comLINK_84212ca4-c025-43e7-bf9e-309ced52e4eb">8.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">How to Take Phentermine and Topiramate Extended-Release Capsules</content>
                  </paragraph>
                  <paragraph>Instruct patients on the dosage titration schedule of phentermine and topiramate extended-release capsules. Advise patients to take phentermine and topiramate extended-release capsules in the morning with or without food <content styleCode="italics">[see Dosage and Administration <linkHtml href="#www.splportal.comLINK_4e521d79-6299-4a58-9e85-f9597825b434">(</linkHtml>
                        <linkHtml href="#LINK_4e521d79-6299-4a58-9e85-f9597825b434">2.2</linkHtml>)]</content>.</paragraph>
                  <paragraph>Brands listed are the trademarks of their respective owners.</paragraph>
                  <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                  <paragraph>Manufactured In Bulgaria By:<br/>
                     <content styleCode="bold">Balkanpharma Dupnitsa AD<br/>
                     </content>Dupnitsa 2600, Bulgaria</paragraph>
                  <paragraph>Manufactured For:<br/>
                     <content styleCode="bold">Teva Pharmaceuticals<br/>
                     </content>Parsippany, NJ 07054</paragraph>
                  <paragraph>Rev. B 12/2024</paragraph>
               </text>
               <effectiveTime value="20241212"/>
            </section>
         </component>
         <component>
            <section ID="LINK_f02ebf33-641d-4f60-8e85-19fe5b2e9277">
               <id root="d7b7e40f-86fa-48fc-b2ef-53cb0cce21b3"/>
               <code code="42231-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL MEDGUIDE SECTION"/>
               <title/>
               <text>
                  <paragraph>Dispense with Medication Guide available at: www.tevausa.com/medguides</paragraph>
                  <table width="1000px" cellspacing="0" cellpadding="5" border="1">
                     <col width="0pt"/>
                     <col/>
                     <col/>
                     <col/>
                     <tbody>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">MEDICATION GUIDE<br/>
                                 </content>
                                 <content styleCode="bold">Phentermine (fen' ter meen) and<br/>
                                 </content>
                                 <content styleCode="bold">Topiramate (toe pir' a mate) Extended-Release Capsules<br/>
                                 </content>
                                 <content styleCode="bold">for oral use, CIV</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What is the most important information I should know about </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Phentermine and topiramate extended-release capsules </content>
                                 <content styleCode="bold">can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Birth defects.</content> If you take phentermine and topiramate extended-release capsules during pregnancy, your baby has a higher risk for birth defects including cleft lip and cleft palate. Your baby may also be smaller than expected at birth. The long-term effects of this areÂ  not known. These defects can begin early in pregnancy, even before you know you are pregnant.<br/>
                                    <content styleCode="bold">Patients who are pregnant must not take </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold">. <br/>
                Patients who can become pregnant should:</content>
                                 </item>
                              </list>
                              <list listType="ordered" styleCode="Arabic">
                                 <item>Have a pregnancy test before taking phentermine and topiramate extended-release capsules and every month while taking phentermine and topiramate extended-release capsules.</item>
                                 <item>Use effective birth control (contraception) consistently while taking phentermine and topiramate extended-release capsules. Talk to your health care provider about how to prevent pregnancy.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">If you become pregnant while taking </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">, stop taking </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> immediately and tell your health care provider right away.</content> Health care providers and patients who become pregnant should report all cases of pregnancy to:</paragraph>
                              <list listType="unordered" styleCode="Square">
                                 <item>FDA MedWatch at 1-800-FDA-1088</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Because of the risk for birth defects (cleft lip and cleft palate), </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> are available through a restricted program called the </content>
                                 <content styleCode="bold">Phentermine and Topiramate</content>
                                 <content styleCode="bold">Â Extended-Release Capsules <content styleCode="bold">Risk Evaluation and Mitigation Strategy (REMS)</content>.</content> Phentermine and topiramate extended-release capsules are only available through certified pharmacies that participate in the Phentermine and Topiramate Extended-Release Capsules REMS. Your health care provider can give you information about how to find a certified pharmacy. For more information, go to www.PhenTopREMS.com or call 1-800-269-6816.</paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Suicidal thoughts or actions.</content> Topiramate, an ingredient in phentermine and topiramate extended-release capsules, may cause you to have suicidal thoughts or actions.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Call your health care provider right away if you have any of these symptoms, especially if they are new, worse, or worry you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Circle">
                                 <item>thoughts about suicide or dying</item>
                                 <item>attempts to commit suicide</item>
                                 <item>new or worse depression</item>
                                 <item>new or worse anxiety</item>
                                 <item>feeling agitated or restless</item>
                                 <item>panic attacks</item>
                                 <item>trouble sleeping (insomnia)</item>
                                 <item>new or worse irritability</item>
                                 <item>acting aggressive, being angry, or violent</item>
                                 <item>acting on dangerous impulses</item>
                                 <item>an extreme increase in activity and talking (mania)</item>
                                 <item>other unusual changes in behavior or mood</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Do not stop </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> without first talking to a health care provider.</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Stopping phentermine and topiramate extended-release capsules suddenly can cause serious problems.</item>
                                 <item>Suicidal thoughts or actions can be caused by things other than medicines. If you have suicidal thoughts or actions, your health care provider may check for other causes.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">How can I watch for early symptoms of suicidal thoughts and actions?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Pay attention to any changes, especially sudden changes in mood, behaviors, thoughts, or feelings.</item>
                                 <item>Keep all follow-up visits with your health care provider as scheduled.</item>
                                 <item>Call your health care provider between visits as needed, especially if you are worried about symptoms.</item>
                              </list>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Serious eye problems</content> which include:
                <list listType="unordered" styleCode="Circle">
                                       <item>any sudden decrease in vision, with or without eye pain and redness,</item>
                                       <item>a blockage of fluid in the eye causing increased pressure in the eye (secondary angle closure glaucoma).</item>
                                    </list>
                                 </item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">These problems can lead to permanent vision loss if not treated.</content> Tell your health care provider right away if you have any new eye symptoms.</paragraph>
                              <paragraph>Phentermine and topiramate extended-release capsules can have other serious side effects. See <content styleCode="bold">âWhat are the possible side effects of </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?â.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Phentermine and topiramate extended-release capsules are a prescription medicine that contains phentermine and topiramate extended-release.Â Phentermine and topiramate extended-release capsules may help adults with obesity, or some adults with overweight who also have weight-related medical problems, to help them lose excess body weight and keep the weight off.</item>
                                 <item>Phentermine and topiramate extended-release capsules should be used with a reduced calorie diet and increased physical activity.</item>
                                 <item>It is not known if phentermine and topiramate extended-release capsules change your risk of heart problems or stroke or of death due to heart problems or stroke.</item>
                                 <item>It is not known if phentermine and topiramate extended-release capsules are safe and effective when taken with other prescription and over-the-counter medicines, or herbal weight loss products.</item>
                                 <item>It is not known if phentermine and topiramate extended-release capsules are safe and effective in children under 12 years old.</item>
                                 <item>Phentermine and topiramate extended-release capsules are a federally controlled substance (CIV) because it contains phentermine and can be abused or lead to drug dependence. Keep phentermine and topiramate extended-release capsules in a safe place, to protect it from theft. Never give your phentermine and topiramate extended-release capsules to anyone else, because it may cause death or harm them. Selling or giving away phentermine and topiramate extended-release capsules is against the law.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Who should not take </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Do not take </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>are pregnant, planning to become pregnant, or become pregnant during phentermine and topiramate extended-release capsule treatment.</item>
                                 <item>have glaucoma.</item>
                                 <item>have thyroid problems (hyperthyroidism).</item>
                                 <item>are taking certain medicines called monoamine oxidase inhibitors (MAOIs) or have taken MAOIs in the past 14 days.</item>
                                 <item>are allergic to topiramate, sympathomimetic amines such as phentermine, or any of the ingredients in phentermine and topiramate extended-release capsules. See the end of this Medication Guide for a complete list of ingredients in phentermine and topiramate extended-release capsules.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">Before taking </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">, tell your health care provider about all of your medical conditions, including if you:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>have or have had depression, mood problems, or suicidal thoughts or behavior.</item>
                                 <item>have eye problems, especially glaucoma. See <content styleCode="bold">âWho should not take </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold">?â</content>
                                 </item>
                                 <item>have a history of too much acid in the blood (metabolic acidosis) or a condition that puts you at higher risk for metabolic acidosis such as
                <list listType="unordered" styleCode="Circle">
                                       <item>chronic diarrhea, surgery, a diet high in fat and low in carbohydrates (ketogenic diet), weak, brittle, or soft bones (osteoporosis, osteomalacia (rickets), osteopenia), or decreased bone density.</item>
                                    </list>
                                 </item>
                                 <item>have kidney problems, kidney stones, or are getting kidney dialysis.</item>
                                 <item>have liver problems.</item>
                                 <item>have seizures or convulsions (epilepsy).</item>
                                 <item>are breastfeeding or plan to breastfeed. Phentermine and topiramate can pass into your breast milk and may harm your baby. You and your health care provider should decide if you will take phentermine and topiramate extended-release capsules or breastfeed. You should not do both.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Tell your health care provider about all the medicines you take,</content> including prescription and over-the-counter medicines, vitamins, and herbal supplements. Phentermine and topiramate extended-release capsules taken with other medicines may affect how each medicine works and may cause side effects.</paragraph>
                              <paragraph>
                                 <content styleCode="bold">Especially tell your health care provider if you take:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Birth control pills.</content> Tell your health care provider if your menstrual bleeding changes while you are taking birth control pills that contain both estrogen and progestin (combination oral contraceptives) and phentermine and topiramate extended-release capsules.</item>
                                 <item>
                                    <content styleCode="bold">Water pills</content> (diuretics) such as hydrochlorothiazide (HCTZ).</item>
                                 <item>
                                    <content styleCode="bold">Any medicines that impair or decrease your thinking, concentration, or muscle coordination.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Carbonic anhydrase inhibitors</content> such as ZONEGRAN<sup>Â®</sup> (zonisamide), DIAMOX<sup>Â®</sup> (acetazolamide) or NEPTAZANE<sup>Â®</sup> (methazolamide).</item>
                                 <item>
                                    <content styleCode="bold">Seizure medicines</content> such as Valproic acid (DEPAKENE<sup>Â®</sup> or DEPAKOTE<sup>Â®</sup>).</item>
                              </list>
                              <paragraph>Ask your health care provider or pharmacist for a list of these medicines, if you are not sure.</paragraph>
                              <paragraph>Know the medicines you take. Keep a list of them to show your health care provider and pharmacist each time you get a new medicine. <content styleCode="bold">Do not</content> start a new medicine without talking to your health care provider.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I take </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Your health care provider should start you on a diet and exercise program when you start taking phentermine and topiramate extended-release capsules. Stay on this program while you are taking phentermine and topiramate extended-release capsules.Â </item>
                                 <item>Take phentermine and topiramate extended-release capsules exactly as your health care provider tells you to take it.</item>
                                 <item>
                                    <content styleCode="bold">Do not</content> change your dose without talking to your health care provider.Â </item>
                                 <item>Take phentermine and topiramate extended-release capsules daily in the morning.</item>
                                 <item>Phentermine and topiramate extended-release capsules can be taken with or without food.</item>
                                 <item>If you miss a dose of phentermine and topiramate extended-release capsules, wait until the next morning to take your usual dose of phentermine and topiramate extended-release capsules. <content styleCode="bold">Do not</content> double your dose.</item>
                                 <item>
                                    <content styleCode="bold">To start treatment with </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Take 1 <content styleCode="bold">phentermine and topiramate extended-release </content>
                                          <content styleCode="bold">3.75 mg (phentermine)/23 mg (topiramate) capsule</content> (Figure A) 1 time each morning for the first 14 days.</item>
                                       <item>After taking phentermine and topiramate extended-release 3.75 mg/23 mg capsule for 14 days, then take 1 <content styleCode="bold">phentermine and topiramate extended-release </content>
                                          <content styleCode="bold">7.5 mg/46 mg capsule</content> (Figure B) 1 time each morning.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">After taking </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold"> for 12 weeks</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Your health care provider may tell you to increase your dose of phentermine and topiramate extended-release capsules if you do not lose a certain amount of weight within the <content styleCode="bold">first</content> 12 weeks of treatment at the recommended dose.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">If your health care provider increases the dose of </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <list listType="unordered" styleCode="Circle">
                                       <item>Take 1 <content styleCode="bold">phentermine and topiramate extended-release </content>
                                          <content styleCode="bold">11.25 mg/69 mg capsule</content> (Figure C) 1 time each morning for 14 days.</item>
                                       <item>After taking 14 days of phentermine and topiramate extended-release 11.25 mg/69 mg capsule, then take <br/>
                    1 <content styleCode="bold">phentermine and topiramate extended-release </content>
                                          <content styleCode="bold">15 mg/92 mg capsule</content> (Figure D) 1 time each morning.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Stopping </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold"> treatment<br/>
                                    </content>Your health care provider should tell you to stop taking phentermine and topiramate extended-release capsules if you have not lost a certain amount of weight after an <content styleCode="bold">additional</content> 12 weeks of treatment on the higher dose.<br/>
                                    <content styleCode="bold">Do not</content> stop taking phentermine and topiramate extended-release capsules without talking to your health care provider. <content styleCode="bold">Stopping </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold"> suddenly can cause serious problems, such as seizures.</content> Your health care provider will tell you how to stop taking phentermine and topiramate extended-release capsules slowly.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Lrule">
                              <renderMultiMedia referencedObject="MM4"/>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM5"/>
                           </td>
                           <td align="center">
                              <renderMultiMedia referencedObject="MM6"/>
                           </td>
                           <td align="center" styleCode=" Rrule">
                              <renderMultiMedia referencedObject="MM7"/>
                           </td>
                        </tr>
                        <tr>
                           <td align="center" styleCode=" Lrule">
                              <paragraph>
                                 <content styleCode="bold">Figure A</content>
                              </paragraph>
                              <paragraph>Phentermine and Topiramate <br/>
            Extended-Release Capsules<br/>
            (3.75 mg/23 mg)</paragraph>
                              <paragraph>White opaque cap and orange opaque body with black printing</paragraph>
                           </td>
                           <td align="center">
                              <paragraph>
                                 <content styleCode="bold">Figure B</content>
                              </paragraph>
                              <paragraph>Phentermine and Topiramate <br/>
            Extended-Release Capsules<br/>
            (7.5 mg/46 mg)</paragraph>
                              <paragraph>White opaque cap and green opaque body with black printing </paragraph>
                           </td>
                           <td align="center">
                              <paragraph>
                                 <content styleCode="bold">Figure C</content>
                              </paragraph>
                              <paragraph>Phentermine and Topiramate <br/>
            Extended-Release Capsules<br/>
            (11.25 mg/69 mg)</paragraph>
                              <paragraph>Light yellow opaque cap and white opaque body with black printing </paragraph>
                           </td>
                           <td align="center" styleCode=" Rrule">
                              <paragraph>
                                 <content styleCode="bold">Figure D</content>
                              </paragraph>
                              <paragraph>Phentermine and Topiramate <br/>
            Extended-Release Capsules<br/>
            (15 mg/92 mg)</paragraph>
                              <paragraph>White opaque cap and dark scarlet opaque body with black printing</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Lrule Rrule">
                              <paragraph>If you take too many phentermine and topiramate extended-release capsules, call your health care provider or Poison Help line at 1-800-222-1222 or go to the nearest emergency room right away.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What should I avoid while taking </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>
                                    <content styleCode="bold">Do not get pregnant while taking </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold">.</content> See <content styleCode="bold">âWhat is the most important information I should know about </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold">?â.</content>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Do not drink too much alcohol while taking </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold">.</content> Phentermine and topiramate extended-release capsules and alcohol can affect each other causing side effects such as sleepiness or dizziness.</item>
                                 <item>
                                    <content styleCode="bold">Do not drive a car, operate heavy machinery, or do other dangerous activities until you know how </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold"> affect you.</content> Phentermine and topiramate extended-release capsules can slow your thinking and motor skills and may affect vision.</item>
                              </list>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the possible side effects of </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">? </content>
                              </paragraph>
                              <paragraph>
                                 <content styleCode="bold">Phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> can cause serious side effects, including:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disk">
                                 <item>See âWhat is the most important information I should know about phentermine and topiramate extended-release capsules?â.</item>
                                 <item>
                                    <content styleCode="bold">Mood changes and trouble sleeping.</content> Phentermine and topiramate extended-release capsules may cause depression or mood problems, and trouble sleeping. Tell your health care provider if symptoms occur.</item>
                                 <item>
                                    <content styleCode="bold">Concentration, memory, and speech difficulties.</content> Phentermine and topiramate extended-release capsules may affect how you think and cause confusion, problems with concentration, attention, memory, or speech. Tell your health care provider if symptoms occur.</item>
                                 <item>
                                    <content styleCode="bold">Slowing of growth.</content> Phentermine and topiramate extended-release capsules may slow the increase in height in children when used for a long time.</item>
                                 <item>
                                    <content styleCode="bold">Increases of acid in bloodstream (metabolic acidosis).</content> If left untreated, metabolic acidosis can cause brittle or soft bones (osteoporosis, osteomalacia (rickets), osteopenia), kidney stones, can slow the rate of growth in children, and may possibly harm your baby if you are pregnant. Metabolic acidosis can happen with or without symptoms. Sometimes people with metabolic acidosis will:
                <list listType="unordered" styleCode="Circle">
                                       <item>feel tired</item>
                                       <item>not feel hungry (loss of appetite)</item>
                                       <item>feel changes in heartbeat</item>
                                       <item>have trouble thinking clearly<br/>
                                          <br/>
                    Your health care provider should do a blood test to measure the level of acid in your blood before and during your treatment with phentermine and topiramate extended-release capsules.</item>
                                    </list>
                                 </item>
                                 <item>
                                    <content styleCode="bold">Decrease in kidney function.</content> Phentermine and topiramate extended-release capsules may cause a decrease in kidney function. Your health care provider should do a blood test to measure your kidney function before and during treatment with phentermine and topiramate extended-release capsules.</item>
                                 <item>
                                    <content styleCode="bold">Possible seizures if you stop taking </content>
                                    <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                    <content styleCode="bold"> too fast.</content> Seizures may happen in people who may or may not have had seizures in the past if you stop phentermine and topiramate extended-release capsules too fast. Your health care provider will tell you how to stop taking phentermine and topiramate extended-release capsules slowly.</item>
                                 <item>
                                    <content styleCode="bold">Kidney stones.</content> Drink plenty of fluids when taking phentermine and topiramate extended-release capsules to help decrease your chances of getting kidney stones. If you get severe side or back pain, or blood in your urine, call your health care provider.</item>
                                 <item>
                                    <content styleCode="bold">Decreased sweating and increased body temperature (fever).</content> People should be watched for signs of decreased sweating and fever, especially in hot temperatures. Some people may need to be hospitalized for this condition.Â </item>
                                 <item>
                                    <content styleCode="bold">Low potassium.</content> Phentermine and topiramate extended-release capsules can increase your risk of low potassium levels. Your health care provider should do a blood test to measure the level of potassium in your blood before and during treatment with phentermine and topiramate extended-release capsules.</item>
                                 <item>
                                    <content styleCode="bold">Serious skin reactions.</content> Phentermine and topiramate extended-release capsules may cause a severe rash with blisters and peeling skin, especially around the mouth, nose, eyes, and genitals (Stevens-Johnson Syndrome). Phentermine and topiramate extended-release capsules may also cause a rash with blisters and peeling skin over much of the body that may cause death (Toxic Epidermal Necrolysis). Call your health care provider right away if you develop a skin rash or blisters.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Common side effects of </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> in adults include:</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>numbness or tingling in the hands, arms, feet, or face (paraesthesia)</item>
                                 <item>dizziness</item>
                                 <item>change in the way foods taste or loss of taste (dysgeusia)</item>
                                 <item>trouble sleeping (insomnia)</item>
                                 <item>constipation</item>
                                 <item>dry mouth</item>
                              </list>
                              <paragraph>Tell your health care provider if you have any side effect that bothers you or does not go away.</paragraph>
                              <paragraph>These are not all of the possible side effects of phentermine and topiramate extended-release capsules. For more information, ask your health care provider or pharmacist.</paragraph>
                              <paragraph>Call your doctor for medical advice about side effects. You may report side effects to FDA at 1-800-FDA-1088. You can also report side effects to Teva at 1-888-838-2872.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">How should I store </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?</content>
                              </paragraph>
                              <list listType="unordered" styleCode="Disc">
                                 <item>Store phentermine and topiramate extended-release capsules at room temperature between 68Â°F to 77Â°F (20Â°C to 25Â°C).Â  </item>
                                 <item>Keep phentermine and topiramate extended-release capsules in a tightly closed container.</item>
                                 <item>Keep phentermine and topiramate extended-release capsules dry and away from moisture.</item>
                              </list>
                              <paragraph>
                                 <content styleCode="bold">Keep </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold"> and all medicines out of the reach of children.</content>
                              </paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">General Information about the safe and effective use of </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">.</content>
                              </paragraph>
                              <paragraph>Medicines are sometimes prescribed for purposes other than those listed in a Medication Guide. Do not use phentermine and topiramate extended-release capsules for a condition for which it was not prescribed. Do not give phentermine and topiramate extended-release capsules to other people, even if they have the same symptoms you have. It may harm them.</paragraph>
                              <paragraph>You can ask your pharmacist or health care provider for information about phentermine and topiramate extended-release capsules that is written for health professionals.</paragraph>
                           </td>
                        </tr>
                        <tr>
                           <td colspan="4" styleCode=" Botrule Toprule Lrule Rrule">
                              <paragraph>
                                 <content styleCode="bold">What are the ingredients in </content>
                                 <content styleCode="bold">phentermine and topiramate extended-release capsules</content>
                                 <content styleCode="bold">?<br/>
                                 </content>
                                 <content styleCode="bold">Active Ingredient:</content> phentermine hydrochloride and topiramate extended-release<br/>
                                 <content styleCode="bold">Inactive Ingredients:</content> colloidal silicon dioxide, copovidone, ethylcellulose, gelatin, hypromellose, microcrystalline cellulose, polysorbate 80, povidone K-30, sugar spheres (which contain sucrose and corn starch), talc, and titanium dioxide. The 3.75 mg/23 mg strength also contains iron oxide red and iron oxide yellow. The 7.5 mg/46 mg strength also contains FD&amp;C Blue #2 and iron oxide yellow. The 11.25 mg/69 mg strength also contains iron oxide yellow. The 15 mg/92 mg strength also contains iron oxide red. The imprinting ink contains ammonium hydroxide, iron oxide black, propylene glycol, and shellac glaze.</paragraph>
                              <paragraph>
                                 <content styleCode="italics">
                                    <content styleCode="italics">Pediatric use information is approved for Vivus LLC's Qsymia<sup>Â®</sup> (phentermine and topiramate) extended-release capsules. However, due to Vivus LLC's marketing exclusivity rights, this drug product is not labeled with that information</content>.</content>
                              </paragraph>
                              <paragraph>Brands listed are the trademarks of their respective owners.</paragraph>
                              <paragraph>Manufactured In Bulgaria By: <content styleCode="bold">Balkanpharma Dupnitsa AD</content>, Dupnitsa 2600, Bulgaria<br/>
            Manufactured For: <content styleCode="bold">Teva Pharmaceuticals</content>, Parsippany, NJ 07054<br/>For more information call Teva at 1-888-838-2872.</paragraph>
                           </td>
                        </tr>
                     </tbody>
                  </table>
                  <paragraph>This Medication Guide has been approved by the U.S. Food and Drug Administration.Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â  Â Rev. B 12/2024</paragraph>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM4">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-4.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM5">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-5.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM6">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-6.jpg"/>
                     </value>
                  </observationMedia>
               </component>
               <component>
                  <observationMedia ID="MM7">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-7.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_ae116874-1df0-4550-8b7b-30fd0630fa52">
               <id root="436f285b-a605-4bed-8ceb-5e7518df5ee5"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0480-3297-56<br/>Phentermine and Topiramate Extended-release CapsulesÂ  Â CIV<br/>3.75 mg/23 mg<br/>PHARMACIST: Dispense the accompanying Medication Guide to each patient.<br/>Rx only<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM8"/>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM8">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-8.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_b89f58c7-d13b-4579-89ff-56daddd3ef7a">
               <id root="249d5a3c-39b9-4ef2-9bbf-692a1e6e0564"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0480-3296-56<br/>Phentermine and Topiramate Extended-release CapsulesÂ  Â CIV<br/>7.5 mg/46 mg<br/>PHARMACIST: Dispense the accompanying Medication Guide to each patient.<br/>Rx only<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM9"/>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM9">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-9.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_934521d1-f8bf-4f3f-822c-f7a7b291531c">
               <id root="96cd8b4c-156e-4a3e-9ad8-b1fe3083d3f7"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0480-2299-56<br/>Phentermine and Topiramate Extended-release CapsulesÂ  Â CIV<br/>11.25 mg/69 mg<br/>PHARMACIST: Dispense the accompanying Medication Guide to each patient.<br/>Rx only<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM10"/>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM10">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-10.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="LINK_142e9a17-d176-4b01-b6bf-08fa1bda72e7">
               <id root="2d307793-0a1d-4374-9343-982a56f592e0"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL.PRINCIPAL DISPLAY PANEL</title>
               <text>
                  <paragraph>NDC 0480-3295-56<br/>Phentermine and Topiramate Extended-release CapsulesÂ  Â CIV<br/>15 mg/92 mg<br/>PHARMACIST: Dispense the accompanying Medication Guide to each patient.<br/>Rx only<br/>30 Capsules</paragraph>
                  <renderMultiMedia referencedObject="MM11"/>
               </text>
               <effectiveTime value="20241212"/>
               <component>
                  <observationMedia ID="MM11">
                     <text>1</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="image-11.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>